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ABSTRACT 
Hidradenitis suppurativa (HS) is a chronic inflammatory disease of mainly unknown 
aetiology which in most cases involves axillae or groins and that can last for decades. 
In this thesis different clinical aspects of HS are studied: development of a clinical 
scoring system, relation to smoking and obesity, outcome of laser surgery, bacteraemia 
in HS patients and distribution of the neuroendocrine marker protein gene product 
(PGP) 9.5 in HS skin biopsies. 
 
In Paper I the objective is to evaluate the modified Hidradenitis Suppurativa Score 
(HSS) and to study the impact of BMI and smoking habits on disease severity. 
Altogether 246 HS patients completed the Dermatology Life Quality Index (DLQI) 
questionnaire and 115 were scored by HSS. Points were given for regions, types of 
lesion (nodules, fistulas), total area involved, and whether lesions were separated by 
normal skin. A positive correlation of fair degree between HSS and DLQI was found, 
as well as significant higher median scores in more advanced HS, in smokers compared 
to non smokers and in obese women compared to those of normal weight, respectively. 
The results indicate that the HSS reflects disease severity, and may be a relevant 
outcome measure in clinical trials. 
In Paper II scanner-assisted carbon dioxide laser treatment with subsequent healing by 
secondary intention is evaluated in 34 HS patients, with in total 67 operating sites. 
They were interviewed by telephone about recurrences and end results, after a mean 
follow-up time of 34.5 (range 7–87) months. Four patients had had recurrences in one 
of the treated areas. In twelve cases, lesions had developed separated from the initial 
surgical site by >5 cm. Twenty-five patients had flare-ups of HS lesions in another 
anatomical region. Eight had no symptoms of HS at all during the follow-up period. 
Mean healing time was 4 (range 3–5) weeks. The conclusion is that scanner-assisted 
carbon dioxide laser treatment of HS is an efficient treatment, well accepted by the 
patients. 
In Paper III the objective is to determine the number and type of bacteria circulating 
in the bloodstream in HS patients undergoing carbon dioxide laser surgery. Blood 
samples were taken before, during and after surgery in 21 patients with HS Hurley 
stage II, and from five healthy controls. Bacterial growth in the first blood sample was 
found in nine patients, from the second in ten and from the third in six. In one patient, 
bacteria were detected in all the three samples. The dominating bacteria were coagu-
lase-negative staphylococci, of which most were subtyped as S. warneri. In six patients 
all samples were negative, which may indicate that the method of surgery itself caused 
no spread of bacteria.  
In Paper IV the presence and distribution of the nerve fibre-marker PGP 9.5 is inves-
tigated by immunohistochemistry. Biopsies were taken from the groin or axilla of 16 
HS patients and 12 healthy controls. The median number of PGP 9.5 positive profiles 
was decreased in lesional epidermis, yet statistically significant only in the groin. A 
similar difference was found in lesional dermis of the axilla, whereas in the lesional 
upper dermis of the groin the median number of profiles was increased. Cells with 
strong PGP 9.5 immunofluorescence were few or absent in epidermis, but significantly 
increased in lesional dermal skin of the groin. It is possible that PGP 9.5 positive nerve 
fibres and cells have pathological roles in HS, but further investigations are needed.  
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1 INTRODUCTION 
Hidradenitis suppurativa (HS, syn. acne inversa) is a chronic, inflammatory, recurrent, 
debilitating skin disease that usually presents after puberty with painful, deep-seated 
inflamed lesions in the apocrine gland-bearing areas of the body; most commonly the 
axillary, inguinal and anogenital regions (Dessau consensus definition).1 HS causes 
substantial negative impact on quality of life due to the burden of purulent discharge, 
odour and pain. 2-5 The disease was described already in the 19th century by two French 
surgeons; in 1833 by Velpeau, who wrote about an axillary phlegmon with slowly and 
sometimes painful inflammation that usually ended in suppuration, and in 1854 by 
Verneuil, who localized the abscesses to the sweat glands and named the disease 
“hidrosadénite phlegmoneuse” in 1864.6 From the beginning of the 20th century it was 
considered a disorder of the apocrine glands, but more recent studies have described HS 
as a disorder of follicular rather than apocrine tissue, and have suggested that apocrine 
involvement rather is secondary to the process that involves the terminal hair follicle.7-9 
 
1.1 CLINICAL FEATURES 
The predilected HS-regions are inverse areas such axillae and groins, but the gluteal, 
perineal or breast region are often affected as well, with differences between women 
and men.10-12 Genito-femoral lesions are more common in women while perianal 
lesions as well as buttocks are more common in men.13 Axillary involvement is 
common in both genders. HS is a clinical diagnosis based on three main features: deep 
seated nodules and or fibrosis, typical localisations and relapses and chronicity (Figure 
1 and 2).13 Differential diagnoses include furunculosis and other staphylococcal skin 
infections, epidermoid cysts and in perianal cases sometimes Crohn’s disease.13 The 1-
year prevalence of HS has been estimated to 1% in the general population in several 
studies, 14, 15 and a point prevalence of 4.1% was found among younger people 
attending a STD-clinic in Denmark.14  Onset of the disease is principally after puberty 
with a reported mean age of 21.8 years in a British study16 and median age at onset 20 
years in a French study of 302 HS patients.10 There are some case reports of earlier 
onset, however.17 Women are more commonly affected than men with an estimated 
ratio of 2–5:1.18 In women, HS may persist to the climacteric, and onset after 
menopause is uncommon.19 About one third of the patients report a positive family 
history of similar symptoms in a first-degree relative.10, 16 A familial form of HS with 
findings that support the concept of autosomal dominant inheritance has been described 
in Great Britain,20 as well as one disease gene locus in a Chinese family.21 The 
condition may remain relatively mild, but nevertheless distressing, ranging from a few 
but recalcitrant suppurating lesions to an advanced, widespread and disabling disease 
that lasts for years or decades.22 In a study of 110 patients with mean age 40.1 years, 
the reported mean duration of HS was 18.8 years, and the majority still had experienced 
active disease within the last year.16 
 
1.2 AGGRAVATING FACTORS 
Smoking and obesity are frequent among HS patients and are considered plausible risk 
factors.1, 10, 15, 19, 23 König et al. found in a case-control study of 84 HS patients a rate of 
active cigarette smokers of 88.9% whereas 6.4% had never smoked.23 
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An epidemiological study showed a strong association between HS prevalence and 
current smoking as well as with high body mass index (BMI).15 A correlation between 
increased BMI and HS severity has also been described.10 Aggravating factors 
mentioned by patients include sweating or heat, stress or fatigue and tight clothing or 
friction.16 So far it has not been proved that skin irritation, patterns in use of cosmetics, 
use of oral contraceptives or clinical signs of androgenisation would play a significant 
role in HS development.3, 24 However, aggravating factors in HS may be highly 
individual. 
 
1.3 SCORING AND CLASSIFICATION 
The best measures for clinical medicine should be acceptable to use in clinical or 
research settings and generate interpretable results. To use results of clinical trials to 
improve the quality of care, valid and interpretable severity scores are needed. Validity 
testing is a challenge when no “gold” standard exists and the variables are complex or 
multifactorial. Another issue of particular importance in dermatology is that patients 
with the same clinical picture and disease severity often experience their illness with 
varying impact on the well-being.25 For subjective measurement of the disease burden 
in dermatological conditions, the Dermatology Life Quality Index (DLQI) developed 
by Finlay and Khan,26 is the most established life quality instrument. HS causes a high 
degree of morbidity, with the highest scores obtained for the pain caused by the disease, 
von der Werth and Jemec concluded in a study that included 114 patients.5 The mean 
DLQI score for HS was higher than for previously studied skin diseases, and correlated 
with disease intensity, as expressed by lesions per month.5  
 
 
Figure 1. An inflamed nodule in a mild case of HS (Hurley I). 
 
 
Staging of HS according to Hurley 
Traditionally, the Hurley clinical grading system, with three stages that ranges from 
localised inflammation to fulminant disease, has been used.27 Hurley stage I consists of 
one or more abscesses with no sinus tract or cicatrisation and stage II consists of one or 
more widely separated recurrent abscesses, with a tract and scarring. The most severe 
cases (stage III) are described as having multiple interconnected tracts and abscesses 
throughout the entire affected area (Figure 1 and 2).27 Hurley clinical grading is well 
suited for classification or staging, and may serve as base for choice of treatment. 
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However, for clinical trials that require a more detailed measurement of changes it is 
important to have a more dynamic and precise scoring system, by adding clinical 
details to the staging. This led to the development that started a few years ago, of a 
proposed scoring system.28 This system has since then been continuously upgraded.  
 
   
Figure 2 (a-c). Axillary lesions including nodules, scars, comedones and fistulas in three 
patients with (a, b) moderate (Hurley II) and (c) severe (Hurley III) hidradenitis suppurativa. 
 
 
1.4 PATHOPHYSIOLOGICAL ASPECTS 
HS has been known as a clinical entity since more than 150 years, but the etio-
pathogenesis is still unclear to a large extent, even though there are many hypotheses 
concerning infection, genetics, immunity, hormones, tobacco et cetera that are raised 
and discussed.1 Histopathological studies have shown that an early change in HS is 
hyperkeratosis of the infundibulum of the terminal hair follicle, which in turn give rise 
to horny filling, subsequent occlusion and dilation. Inflammatory changes occur, 
leading to perifolliculitis.9, 29 The cellular infiltrate consists of neutrophils, lymphocytes 
and histiocytes. Another early inflammatory event is a segmental rupture of the 
follicular epithelium, followed by spilling of foreign body material, such as 
corneocytes, bacteria, sebum products, and hairs into the dermis. The dumping of 
foreign products initiates an inflammatory response provoking foreign body granuloma, 
and epithelial strands encapsulate the necrotic tissue.30 Yu and Cook7 observed 
squamous epithelium-lined structures that probably represent abnormal dilated hair 
follicles, which was a more constant diagnostic feature in hidradenitis suppurativa than 
inflammation of apocrine glands which appeared to be a secondary phenomenon.7 
Attanoos et al.8 have concluded that follicular occlusion by keratinous material, with 
subsequent active folliculitis and secondary destruction of the skin adnexae and 
subcutis, occur as an integral step in the pathogenesis of HS.8 In chronic lesions an 
infiltrate, granulation tissue, giant cells subcutaneous abscesses and sinus tracts may be 
 (a)  (b) (c) 
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found.31 One recently published histopathological investigation found, in addition to 
follicular hyperkeratosis, hyperplasia of follicular epithelium and perifolliculitis, also 
epidermal psoriasisform hyperplasia and a subepidermal interfollicular inflammatory 
infiltrate, where some of the lymphocytes showed epitheliotropism.32  
Sinus tracts, which are a hallmark of HS, represent a phenomenon where non-
malignant keratinocytes proliferates to infiltrative growth. Epithelial lining in sinus 
tracts is heterogeneous and comprises different phenotypes of pathological squamous 
cell epithelium that expresses various cytokeratins and desmosomal proteins that differ 
from normal epithelium.31, 33 Gniadecki and Jemec hypothesised that sinus formation 
could represent an aberrant epidermal repair response executed by an activated special 
subpopulation of stem cell like keratinocytes capable of non-malignant infiltrative 
growth in the dermis and subcutis.34  
Although the apocrine gland has been regarded to be affected as a secondary event, it 
may be hypothesised that there are factors, for instance an abnormal apocrine secretion 
as suggested by Revuz, which could be a triggering factor of HS.1 Another potential 
component of the pathogenesis could be the anti-microbial peptides, which in other 
conditions are known to exert both pro- and anti-inflammatory functions and induce 
keratinocyte proliferation.1 Smoking is a suspected risk factor, but without evidence of 
causality. In an experimental study of non-neuronal acetylcholine and its receptor in 
organotypic cultures and HS skin a strong immunoreactivity around follicular 
infundibulum has been shown.35 This could indicate a mechanism by which tobacco 
promotes infundibular epithelial hyperplasia and thus follicular plugging,35 and provide 
an explanation of why smokers are mostly affected by HS. It would also fit well with 
findings of microcomedones as an early pathogenic event as proposed by Sellheyer and 
Krahl.1, 36 HS has some morphological similarities to acne, but in contrast to acne no 
significant abnormality in sebaceous gland activity has been shown.37 
 
1.4.1 Microbiology 
The clinical relevance of bacterial findings in hidradenitis suppurativa (HS) is contro-
versial. The bacteria are sometimes considered contaminants from the normal skin flora 
or as secondary infection in a previously sterile process.38 Interpretation of the results of 
bacteriological examinations from the surface of HS lesions is obscured by the possible 
contamination of resident skin bacteria.39 Bacterial cultures from HS lesions are often 
polymicrobial and have a predominance of anaerobic bacteria.40 In a study of axillary 
HS, the aerobic bacteria found were S. aureus, Streptococcus pyogenes and Pseudomo-
nas aeruginosa. The most frequently isolated anaerobes were Peptostreptococcus spp 
and Prevotella spp.40 Another study has shown that coagulase-negative staphylococci 
(CoNS) were the most common bacteria found in the deeper portions of chronic HS-
lesions, and Staphylococcus aureus was the second.39 Peptostreptococcus was the most 
common anaerobic organism.39  
The normal microflora of the skin varies significantly depending on amount of seba-
ceous glands as well as if the areas are moist or dry. The prevalence of propionibacteria 
increases with age and the activation of the apocrine sweat glands at puberty plays an 
important role in the colonisation process.41 This may theoretically contribute to the age 
of onset of HS. Propionibacteria produce propionic acid and other enzymes that may 
contribute to tissue damage. Although Propionibacterium species are rarely regarded as 
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pathogens, these organisms cause serious infections in some cases.42 P. acnes has been 
associated with late postoperative infections of implants such as prosthetic heart valves, 
intraocular lenses and shunts.43 Among the CoNS, Staphylococcus epidermidis is an 
important resident, colonizing moist areas of the skin, preferentially in the upper part if 
the body.38 It is also commonly isolated from implants. The ability of these bacteria to 
colonise polymer surfaces and form a multi-layered biofilm is of particular importance 
in the pathogenesis of foreign body-associated infections. Other potential virulence 
factors of S. epidermidis and S. warneri include the formation of extracellular enzymes 
and toxins.44-46 
Simple infection is not the main cause of HS, but lesions may be worsened by secon-
dary infection. In the later stages of the disease, bacterial infection seems to be a risk 
factor for destructive scarring and extension of the lesions.47 
 
1.4.2 The neuroendocrine system 
Various inflammatory skin diseases such as atopic dermatitis, psoriasis, seborrhoeic 
eczema, prurigo nodularis and lichen planus have long been recognized by dermatolo-
gists to worsen in response to psychological stress.48 The underlying mechanism is not 
fully understood, but in recent years knowledge about some of the mechanisms behind 
the so-called neuroendocrine, or neuroimmunoendocrine system, has increased.49-55 The 
“brain-skin connection” includes neurohormones, neurotrophins, neurotransmitters and 
neuropeptides, which in response to stress can interact with the vascular, metabolic and 
immune system, with immunological changes that range from immunosuppression to 
inflammation.49 Between the nervous system, via activation of the hypothalamic-pitui-
tary-adrenal (HPA)-axis with hormone release, upregulation of substance P (SP) and 
calcitonin gene-related peptide (CGRP), and the skin, which acts as both a target for 
and a producer of several of the substances, there is a cross-talk. 49, 53, 56 These systems 
are part of the allostasis, a concept where physiologic systems within the body fluctuate 
to meet demands from external forces, e.g. stress.57 Among various stress mediators, 
CRH (corticotropin-releasing hormone), ACTH (adrenocorticotropic hormone), SP, 
CGRP, SCF (stem-cell factor) and NGF (nerve growth factor) activate mast-cells in the 
skin. In addition, the neuropeptides SP and NGF trigger mast-cell degranulation, with 
secretion of proinflammatory mediators and vasoactive substances, contributing to 
vasodilatation and inflammation.49  
Knowledge is sparse regarding involvement of the neuroendocrine system in HS, but in 
the light of the knowledge that certain neuropeptides play an important role in the 
pathogenesis of inflammatory skin diseases, it could be assumed that they are engaged 
in HS as well. There are several markers for the neuroendocrine system.53, 54, 58 One is 
the general neuronal marker protein gene product (PGP) 9.5,59 which is an ubiquitin C-
terminal hydroxylase found in neurons and nerve fibers of central and peripheral 
nervous system, many neuroendocrine cells, renal tubules, spermatogonia, Leydig cells 
of testis and ova.60 The presence and distribution of PGP 9.5 has previously been 
studied in various dermatoses,61-69 but not in HS. 
 
1.5 THERAPY 
A number of treatments exist, based on whether HS is regarded as an infection, a type 
of acne or a separate inflammatory disease. Treatments with immunosuppressive 
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agents, anti-inflammatory drugs, antibiotics and oestrogens are of value in some 
patients.70 Currently, curative treatment consists mainly of surgery, but adjuvant 
medical treatment is often needed, and is in many cases appropriate as single therapy. 
The selection of treatment modality depends on several factors, including HS stage, 
anatomical location, frequency of exacerbation and the patient’s condition and 
preference. 
 
1.5.1 Medical treatment 
Several different types of topical therapy have been tried in HS, although there are few 
randomized controlled clinical trials. Topical treatment can be effective in milder cases 
and as adjunct therapy in more advanced disease, to reduce inflammation and suppura-
tion and for maintenance of therapeutic results.71 The only topical treatment that so far 
has been studied in randomized controlled trials (RCT) is clindamycin, which has been 
shown superior to placebo.72 Clemmensen evaluated 27 patients that were treated with 
1% clindamycin or placebo twice daily, with significant improvement of abscesses and 
pustules but not of inflammatory nodules at 1 and 2 months.72 Topical clindamycin has 
in another RCT been compared to systemic tetracycline in a double blind study of 46 
HS patients.73 Both treatments showed a progressive improvement in patient and physi-
cian overall assessment during the three months; abscesses were reduced after three 
months, but the soreness score reported by the patients did not change. There were no 
significant differences between the two treatments.73 Azelaic acid, topical antibiotics 
other than clindamycin and corticosteroids have also been tested, but await formal 
studies.71 Intralesional steroid (triamcinolone) injection, which is effective in cystic 
acne, is sometimes used with effect on inflamed lesions.71  
Systemic treatment can be divided into antibiotics, retinoids, hormonal modulators and 
immunosuppressants. Tetracycline, as mentioned above,73 is effective in treatment for 3 
months or longer. Long-term treatment with rifampicin and clindamycin in combina-
tion has been used, and recent publications report effect on severe HS.74-76 Unlike the 
results in treatment of severe acne, the effect of systemic retinoids, in particular isotre-
tionin, has not been satisfactory in HS, but still successful in some patients. A long-
term follow-up of 68 patients treated with isotretionin showed that 23.5% of the HS 
patients cleared during therapy and 16.2% maintained their clearance during the follow-
up period of in mean 46 months.77 The generally unsatisfactory therapeutic effect of 
retinoids could at least partly be explained by the fact that sebum excretion is not in-
creased in HS.37 Case reports78 and one RCT79 that evaluated combination therapy with 
cyproterone acetate have suggested that antiandrogen therapy may be of value in 
women with HS. A more recent study of 64 female HS patients found in a retrospective 
analysis that the response to antiandrogen therapy was superior to antibiotics; 55% vs. 
26% of treated patients responded to the given therapy.80 Finasteride has also reported 
efficacy in small case series.81, 82 Immunosuppressive therapies have been used with 
varying results. While methotrexate was of limited value in three patients,83 two cyc-
losporine-treated HS patients were improved,84 in line with two earlier case reports.85, 86 
Improvement was noted within 4–12 weeks in five patients treated with dapsone at 
doses ranging between 25 and 150 mg/day. All patients required maintenance therapy 
to sustain their disease control.87 Short courses of antibiotics or systemic steroids are 
sometimes used in periods of acute exacerbation.11 Interestingly, in a study of the natu-
ral history of HS, it was observed that the mean time for an acute boil to resolve was 
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6.9 days, which roughly equals a short antibiotic course.16 In recent years several 
publications of off-label treatment with tumour necrosis factor-alpha (TNF-α) inhibitors 
(infliximab, etanercept, adalilumab) describe varying, but mostly positive effect on 
HS.88 Initially, patients with Crohn’s disease with concomitant HS showed improve-
ment when treated with infliximab.89, 90 All medical treatment options mentioned have 
potential adverse effects and contraindications that need to be taken into consideration, 
in addition to the patient’s circumstances and disease burden. 
 
1.5.2 Surgery 
For early disease stages, smaller local excisions can be performed, but for more wide-
spread disease wide excisions, beyond the clinical borders of activity, are needed, 
regardless of the location. It has been shown that the extent of surgery affects the recur-
rence rates and the disease-free interval after surgery.91 HS recurred in patients who had 
undergone drainage procedures only, and incision by lancing should therefore be 
avoided. After limited excision and radical wide excision the recurrence rates were 
lower.91 Kagan et al reported a surgical treatment algorithm based on the extent of in-
volvement, chronicity, and comorbid conditions, where excision and primary closure 
was used for localized disease; wide excision with or without skin grafting was used for 
diffuse disease.92 After wide excision the skin grafting and flaps sometimes brings less 
good cosmetic outcome and discomfort including the donor site, and healing by granu-
lation (secondary intention) would be preferred, as shown in some publications.93, 94 
However, the wound healing time may be very long, up to three months after large ex-
cision areas.95 Treated patients have in another study of secondary intention healing 
reported minimal inconvenience, analgesic requirements, or interruption of daily 
activities.96  
 
1.5.3 Carbon dioxide laser surgery 
The use of carbon dioxide laser treatment followed by secondary intention healing in 
HS was first described by Dalrymple and Monaghan,97 then by several authors during 
the past two decades.98-100 The CO2-laser emits a beam at a wavelength of 10600 nm 
that is absorbed by biological tissues since the target of interaction is water. Small lym-
phatic vessels as well as blood vessels less than approximately 0.5 cm in diameter are 
sealed with the laser, resulting in an almost bloodless operating field and potentially 
less postoperative edema.101 It can be used with a small-diameter spot size to cut or a 
broad-diameter spot to vaporise tissue.101 In HS cases the aim is to achieve complete 
radical ablation of diseased tissue combined with preservation of healthy tissue. Previ-
ously, a free-hand technique was used,99 but nowadays the procedure is facilitated and 
also safer by using a carbon dioxide laser with a microprocessor-controlled flash scan-
ner that ablates the tissue in an even and controlled manner. Also, thermal diffusion is 
time dependent and can be reduced if the laser energy is delivered to the tissue for less 
than the thermal relaxation time, by scanning the laser beam rapidly over the tissue area 
in a spiral type pattern that maintains laser exposure of any spot to less than a millisec-
ond, and therefore reducing the risk of necrosis or thermal injury of adjacent tissue.101 
Two recent publications evaluate CO2-laser treatment in cutting mode in nine cases of 
recalcitrant disease,102 and in 61 patients using the laser excision and marsupialisation 
technique,103 with low recurrence rates and high degree of patient satisfaction. 
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Healing time by secondary intention after CO2-laser of HS has been reported to 3–8 
weeks,98, 99 although some cases of delayed healing may occur.  
 
1.6 ASSOCIATED DISEASES 
HS has been associated with various dermatologic disorders including Dowling Degos 
disease and the follicular occlusion tetrad, but also other conditions, for example 
arthritis and Crohn’s disease.104 The follicular occlusion tetrad consists of acne 
conglobata, hidradenitis suppurativa, dissecting folliculitis of the scalp and pilonidal 
sinus.2 Scrotal or pubic lymph edema or elephantiasis may arise as a complication of 
chronic inflammation and repeated episodes of cellulitis. Association between HS and 
Crohn’s disease have been recognized in several case reports,105 and in a recent a pilot 
study 158 patients with inflammatory bowel disease (IBD) were interviewed about 
recurrent painful boils in the axillae and/or groin.106 Twenty-five people (16%) 
responded that they had experienced painful boils in the axillae and/or groin, of whom 
17 were patients with Crohn’s disease (17%) and eight had ulcerous colitis (14%).106 
Longstanding cases of HS may be complicated by squamous cell cancer (SCC), secon-
dary to chronic inflammation.3, 16, 107, 108 In a Swedish study it was found that the risk of 
developing any cancer increased by 50% (relative risk of 1.5) in a cohort of 2119 pa-
tients that had been hospitalized for HS, compared with the age- and sex-matched 
general population during the time of the study, based on 73 observed cases.107 Statisti-
cally significant risk elevations were observed for squamous cell carcinoma (SCC) of 
the skin (5 cases), buccal cancer (5 cases), and primary liver cancer (3 cases), but the 
latter two associations should be interpreted cautiously because of multiple significance 
testing and few observed cases that may have generated chance findings.107 Almost all 
HS associated SCC are located in the gluteal area, and are mostly seen in men.11 
Constantinou et al.108 reviewed in 2008 forty-three published cases of SCC as a 
complication to HS. Thirty-six cases had perianal location and mean duration of HS 
before development of SCC was 24 years. It was in that review concluded that although 
HS is a common condition, it rarely is associated with SCC.108 
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2 AIMS 
In recent years more attention has been paid to hidradenitis suppurativa (HS) and new 
therapies are discussed, which requires tools to measure disease activity and treatment 
outcome. The general aim of this project was to develop an objective scoring system 
for HS, in order to evaluate disease severity and treatment methods including carbon 
dioxide (CO2)-laser. The aim was also to study some aspects of potentially pathogenic 
events in HS.  
The specific aims of the individual papers were: 
Paper I: To evaluate the modified Hidradenitis Suppurativa Score (HSS) and to study 
the impact of body mass index (BMI) and smoking habits on disease severity. In 
addition life quality, measured by the Dermatology Life Quality Index (DLQI), in HS 
patients was investigated and correlated to HSS. 
Paper II: To evaluate a surgical method for treatment of Hurley stage II hidradenitis 
suppurativa; vaporisation by CO2-laser with micro-processor controlled scanner in 
continuous mode, with subsequent healing by secondary intention. 
Paper III: To determine the number and type of bacteria circulating in the bloodstream 
in patients with HS undergoing surgical treatment with the carbon dioxide laser vapori-
sation technique. 
Paper IV: To investigate the presence and density of the nerve fibre-marker protein 
gene product 9.5 (PGP 9.5), by immunohistochemistry, in skin biopsies from patients 
with hidradenitis suppurativa. 
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3 MATERIALS AND METHODS 
3.1 SUBJECTS 
The patients were selected as consecutive clinical cases referred to a centre with special 
interest in the disease at Department of Dermatology, Karolinska University Hospital, 
Huddinge, Sweden. The diagnosis of HS was based on history and clinical presentation 
at the examination. The study patients and control subjects gave informed consent and 
the local ethics committee had approved the study protocols. 
Paper I: The patients were selected as consecutive clinical cases referred during 
seven years (January 2001 – April 2008). 251 patients were included, of which 246 
completed the DLQI questionnaire, and 115 were assessed by HSS (2004 and on-
wards). The comparison of DLQI and HSS is based on the 110 patients that were 
evaluated both by HSS and DLQI. 11 patients were excluded because of psychiatric 
disorder, mental retardation or language difficulties. 
Paper II: Thirty-four patients were evaluated after treatment; 31 women and 3 men, 
with a mean age of 33.9 (range 15–55) years, who had had HS for a mean of 13.4 
(range 1–35) years and more than 3 recurrences of suppurating lesions in the year be-
fore inclusion in the study. All lesions had been classified as Hurley stage II27. The 
mean follow-up time after carbon dioxide laser surgery was 34.5 (range 7–87) months.  
Paper III: A total of twenty-one HS patients (20 females and 1 male) with a mean age 
of 36 (range 20–55) years, were included in the study. The patients were undergoing 
carbon dioxide laser surgery. Five healthy persons, all females, with a mean age of 36 
(range 23–48) years and not undergoing any kind of operation, were used as controls. 
Paper IV: Sixteen HS patients (14 females and 2 males) with a mean age of 41 (range 
25–61) years were included in the study. All patients had had one or more active suppu-
rating lesion in the groin or axilla during the last 12 months. The patients were selected 
as consecutive clinical cases, December 2005 – January 2007. Twelve healthy persons 
(9 females and 3 males) with a mean age of 41.5 (range 29–59) years were used as 
controls. 
 
3.2 METHODS 
3.2.1 Clinical procedures 
Hidradenitis Suppurativa Score (HSS) (Paper I) 
The HSS is a revised version of a former suggestion for uniform variables when evalu-
ating treatment outcome in HS.28 The following is recorded by the dermatologist: the 
anatomical regions involved; axilla, groin, gluteal (left/right) or other region, 3 points 
per region. The number and scores of lesions (nodule 1, fistula 6 points) are calculated 
for each region. The longest distance between two relevant lesions (or size of lesion if 
single) in each region: less than 5 cm; 1, 5–10 cm; 3, more than 10 cm; 9 points. Are all 
lesions separated by normal skin? Yes: 0, No (= Hurley III)27: 9 points. Regional scores 
are added, resulting in the patient’s total score, which has an open upper limit of the 
scale. The HSS protocol is shown in Figure 3.  
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A supplementary subjective scoring by the patient is also recommended; soreness or 
pain of the most symptomatic lesion at the time of consultation, by using a visual ana-
logue scale (VAS), graded 0–10. This value is not included in the calculation of the 
score. 
 
 
Hidradenitis Suppurativa Score  
 
 
 
 
 
 
 
 
Patient Report  
(not included in the score): 
Number of boils during the  
latest month: .............. 
 
Soreness of most  
symptomatic lesion:   
VAS (0 - 10) .............. 
 
 
 
 
 
© Karin Sartorius & Jan Lapins 2008 
 
Parameters Points/parameter 
1. Number of regions 
    3 points per region 3 
2. Number and severity of lesions 
    noduli 1 
    fistulae 6 
3. Longest distance between two relevant lesions 
    <   5 cm 1 
    5 - 10 cm 3 
    > 10 cm 9 
4. Lesions clearly separated by normal skin? 
    yes 0 
    no (Hurley III) 9 
 
Right Axilla ..............
noduli & fistulae ..............
longest distance ..............
Hurley III no/yes ..............
 Σ............
Right Groin ..............
noduli & fistulae ..............
longest distance ..............
Hurley III no/yes ..............
 Σ.............
Right Gluteal Region   ..............
noduli & fistulae ..............
longest distance ..............
Hurley III no/yes ..............
 Σ.............
Other Region   ..............
noduli & fistulae ..............
longest distance ..............
Hurley III no/yes ..............
 Σ............
Left Axilla ..............
noduli & fistulae ..............
longest distance ..............
Hurley III no/yes ..............
 Σ.............
Left Groin  ..............
noduli & fistulae ..............
longest distance ..............
Hurley III no/yes ..............
 Σ..............
Left Gluteal Region    ..............
noduli & fistulae ..............
longest distance ..............
Hurley III no/yes ..............
 Σ..............
 
 
 
 
 
 Total sum: ...............................
 
 L
eg
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d 
to
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a 
 
Figure 3. Hidradenitis Suppurativa Score sheet. 
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Dermatology Life Quality Index (DLQI) (Paper I) 
The index consists of ten questions regarding the impact of the skin disease on feelings 
and different aspects of daily life activities during the latest week. Each question is 
scored by the patient from 0 (not at all) to 3 (very much). A total of 30 points is the 
maximum score, where 0–1 is regarded as no effect, 2–5 small, 6–10 moderate, 11–20 
very large and 21–30 as extremely large effect on the patient’s life.109 An authorized 
Swedish translation of DLQI was used in the study. 
 
Anaesthesia (Paper II, III and IV) 
The affected area was outlined with ink. After cleaning of the skin with 0.05 mg/ml 
chlorhexidine solution, the area was anaesthetised by injecting lidocaine 0.5–1.0 mg/ml 
and epinephrine (Xylocaine®adrenalin, AstraZeneca, Södertälje, Sweden). The solu-
tion was injected and infiltrated around and not directly into the affected site to avoid 
direct contact with inflamed tissue and injection into the abscess. In some cases a 
lidocaine prilocaine cream (EMLA®, AstraZeneca) was applied an hour before the in-
jections, to reduce pain.  
 
Scanner-assisted carbon dioxide laser surgery (Paper II and III) 
A Sharplan carbon dioxide laser 1030® (Lumenis Inc., New York, NY, USA) with a 
focusing hand-piece attached to the miniature optomechanical flash scanner delivery 
system, SilkTouch® (Lumenis Inc.) has been used. Since 2005 we have also used a 
Unilas®10600 carbon dioxide laser (Limmer Laser, GmbH, Berlin, Germany) with 
Surgiscan® scanner, in mode Powerscan. Figure 4 shows the two lasers. The scanner 
device generates a focal spot which rapidly and homogeneously spiral scans and covers 
a round area of tissue in the focal plane. The area selected is ablated with the laser 
beam by passing it over the tissues and this is followed by repeated ablations in the 
same manner after removing devitalised tissues by cleaning the surface with a swab 
soaked in 0.9 % sodium chloride. The depth of each level of vaporisation is controlled 
by the selection of power, focal length, scanner-controlled spot-size and the velocity of 
the movements of the hand-held scanner. We have used 20–50 W, 3–6 mm spot-size 
and 12.5 or 18 cm focal length setting. The vaporisation procedure has been repeated 
downwards and outwards until fresh yellow adipose tissue was exposed in the deep and 
relatively thin and anatomically normal skin margins laterally, with no remaining dense 
or discoloured tissue. The vaporisation usually extended to the deep subcutaneous fat or 
fascia.  
 
Postoperative care (Paper II and III) 
The patients remained in the department for 3 hours after the procedure to discover any 
bleeding before leaving. The dressings (hydrofibre dressing, Aquacel®, ConvaTec Ltd, 
Deeside, UK) were initially left on for 2 or 3 days without changing, to avoid early 
bleeding. Thereafter, the wound was cleaned, rinsed with tap-water and the bandage 
changed as often as necessary, sometimes daily, pending complete healing. The wound 
was inspected after one week and then, until it healed, if there were signs of complica-
tions. Routinely, it was also examined at six weeks and at six months. 
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Figure 4. Carbon dioxide lasers with microprocessor controlled scanners. 
 
 
3.2.2 Sampling of specimens and laboratory procedures 
This section is an overview of the methods used in papers III and IV. More detailed de-
scriptions are given in the respective “Materials and Methods” sections of the 
individual papers. 
 
Blood culture technique and identification of microorganisms (Paper III) 
One blood sample was taken from the patients before surgery, one during the operation 
and finally one 10 minutes post-op. The samples were immediately transported to the 
lab, where the blood was cultured by a lysis-filtration technique which had been shown 
to be very sensitive.110-112 The number of bacteria in the samples could be determined 
since a filter catches the microorganisms, and colonies are formed during culturing. 
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A number of bacterial strains were subject to molecular typing by DNA sequence 
analysis. Susceptibility to some antibiotics was tested for two of the CoNS found. 
 
Punch biopsies, immunohistochemical staining and microscopy (Paper IV) 
Punch biopsies were taken from HS lesions and clinically non-involved skin in the 
groin or axilla from patients and from groin or axilla from matched controls. The 
specimens were put in fixative solution and transported to the lab. Serial cryostat sec-
tions were obtained from the biopsies, and stained for indirect immunofluorescence 
according to standard protocols.113 Coded slides were observed and photographed in 
the microscope and PGP 9.5 positive nerve fibre profiles as well as PGP 9.5 positive 
cells were counted. 
 
3.3 STATISTICS 
Paper I: 
Statistical calculations were made with Statistica 8 software (StatSoft Inc). For the 
analyses of correlation and comparison of groups, non parametric methods were 
chosen; Spearman rank order correlation test, Mann-Whitney test, Kruskal-Wallis 
ANOVA and median test. Correlations were interpreted according to Colton as: 
<0.25; weak/little and 0.25–0.50 fair correlation.114 For descriptive statistics of the 
HSS results median values with lower and upper quartiles were chosen and described 
as “median (IQR)” in the text and the figures. Basic facts about patients as well as 
DLQI results in the first section are described by mean values with standard devia-
tion (SD).  
 
Paper II and III: 
Basic facts and background characteristics such as age, disease duration et cetera are 
described as mean values or mean values with standard deviation (SD). 
 
Paper IV: 
Nonparametric statistical analyses were performed, using the Mann-Whitney test for 
comparison between patients and controls, and Wilcoxon matched pairs test for 
involved – non-involved skin in patients. For descriptive statistics of the results, 
median values with interquartile range (IQR) were used. 
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4 RESULTS AND DISCUSSION 
4.1 HSS REFLECTING SMOKING HABITS AND OBESITY (PAPER I) 
A total of 251 consecutive HS patients were included in the study. Basic characteristics 
of the study group are summarised in Table 1. The reported mean ± SD duration of HS 
was 15.5 ± 10.1 (range 1–47) years, and age at onset was 22.1 ± 9.8 (range 9–57) years. 
Ninety-two patients (38%) reported similar symptoms or HS diagnosis in a first-degree 
relative. 70% of the patients were active smokers, 15% former smokers and 16% non-
smokers. Only one male (of 35) was a non-smoker, compared to 38 out of 177 women. 
In average, the patients reported overweight, with a mean ± SD body mass index (BMI) 
of 28.3 ± 6.5. The patients were divided in three BMI classes, defined as 18.5≤ BMI 
<25 kg/m2 normal; 25≤ BMI <30 kg/m2 overweight and BMI ≥30 kg/m2 obese. They 
were relatively evenly distributed with one third of the patients under- to normal 
weight, one third overweight and one third obese. Mean ± SD number of boils per 
month reported by the patients were 2.5 ± 4.0, and soreness of the most symptomatic 
lesion 2.1 ± 2.7, measured by VAS with maximum score 10. Of the 115 patients that 
were evaluated by HSS, eight patients (7 females, 1 male) had Hurley stage I, and 12 (8 
females, 4 males) had Hurley stage III hidradenitis suppurativa. The majority (95 pa-
tients) had Hurley stage II disease. 
 
 
Table 1. Characteristics of the patients (plus-minus values, when given, are means ± SD). 
Variable n Total Women Men 
Age (yrs.) 251 37.5 ± 11.4 36.9 ± 11.1 41.6 ± 12.1 
Gender 251 251  216 (86%) 35 (14%) 
Age at onset (yrs.) 247 22.1 ± 9.8 21.3 ± 9.3 27.0 ± 11.3 
Disease duration (yrs.) 247 15.5 ± 10.1 15.7 ± 9.9 14.7 ± 11.1 
Heredity:  Yes 244 92 (38%) 87 (42%) 5 (14%) 
 No  152 (62%) 122 (58%) 30 (86%) 
Smoker:  Yes 249 173 (70%) 147 (68%) 26 (76%) 
 Former  37 (15%) 30 (14%) 7 (21%) 
 Non  39 (16%) 38 (18%) 1 (3%) 
BMI (kg/m2) 235 28.3 ± 6.5 28.2 ± 6.6 29.1 ± 5.5 
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Hidradenitis suppurativa score (HSS) 
The median (IQR) total HSS recorded was 38 (18–66), range 5–175. There was no sig-
nificant difference in median (IQR) HSS between men; 37 (19–51) and women; 38 
(18–71). The highest median regional score was recorded in the axillary region for the 
whole group of patients, as well as for the women, while the highest median regional 
score among the men was recorded in the groin. The HSS values differed significantly 
between the three patient groups according to Hurley grade, with higher values for 
stage II and III, respectively (Figure 5). Representative photographs of a patient with 
HS Hurley stage II are shown together with the HSS of each region in Figure 6. 
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Figure 5. Hidradenitis Suppurativa Score (HSS) versus Hurley stage for women and men (n = 
115). The difference between the three groups was statistically significant (p < 0.001, Kruskal-
Wallis test). 
 
 
   
Figure 6 (a-d). A 45-year-old woman with HS in the axillae, with a total HSS of 42 points.  
(a,b) Regional score right side 20 points; 2 fistulas, 2 nodules, distance 5-10 cm. (c,d) Regional 
score left side 22 points; 2 fistulas, 4 nodules, distance 5-10 cm. 
(a) (c) (b) (d) 
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Further, in order to analyse HSS according to smoking habits, the study population was 
divided in three groups: non smokers, former smokers and smokers. Figure 7 shows a 
statistically significant difference in median (IQR) HSS between the non smokers; 22 
(10–57), and the smokers; 41 (22–75). The median HSS of former smokers compared 
to the other two groups was not significantly different. The women showed the same 
pattern as for the whole group with higher HSS in non smokers versus smokers, but the 
men did not show the same result, maybe due to a small number, with only one non-
smoker among the scored males. 
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Figure 7. Hidradenitis Suppurativa Score (HSS) versus smoking category for women and men 
(n = 115). The difference between non smokers and smokers was statistically significant (p = 
0.032, Kruskal-Wallis test), but not significant for former smokers compared to the other 
groups. 
 
 
There was a weak positive correlation between BMI and HSS (Figure 8), and non-sig-
nificant differences in HSS between the BMI groups for the whole group of patients; 
with median (IQR) 32 (12–54) for normal, 44 (22–56) for overweight and 50 (18–86) 
for obese patients. The median HSS was significantly lower for the normal weight 
women compared to obese (Figure 9), which was not true for the men.  
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Figure 8. Hidradenitis Suppurativa Score (HSS) versus BMI (n = 107). Correlation coefficient 
according to Spearman R = 0.202, a weak correlation according to definitions by Colton. 
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Figure 9. Hidradenitis Suppurativa Score (HSS) versus BMI category (defined as 18.5≤ BMI 
<25 kg/m2: normal, 25≤ BMI <30 kg/m2: overweight and BMI ≥30 kg/m2: obese) for women (n 
= 86). It shows a statistically significant difference between the normal and the obese group (p 
= 0.013, Kruskal-Wallis test), but not significant for the overweight group compared to the 
other groups. 
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Figure 10. Hidradenitis Suppurativa Score (HSS) versus DLQI (n = 110). Correlation coeffi-
cient according to Spearman R = 0.342, a fair correlation according to definitions by Colton. 
 
 
Dermatology life quality index (DLQI) 
Two hundred and forty-six patients completed the DLQI questionnaire. Mean ± SD 
DLQI for the whole group of patients was 10.3 ± 7.5, and median (IQR) 9 (4–12), 
range 0–30. Men scored higher (median 11) compared to women (median 9). The high-
est scores were recorded for question 1 (soreness, pain), 4 (clothing) and 2 (embarrass-
ment, self consciousness). No statistically significant differences in DLQI score 
between the subgroups according to smoking habits or BMI was found. The HSS was 
positively correlated to DLQI of a fair degree, based on the 110 patients that both were 
scored and had completed the DLQI questionnaire (Figure 10).  
HS causes a high degree of morbidity, which is reflected as high DLQI scores in a 
study by von der Werth and Jemec,5 with a mean DLQI score of 8.9 in 114 patients. 
Wolkenstein et al found probably a similar degree of morbidity in 61 consecutive HS 
patients, although their result is not directly comparable since VQ-Dermato, a French 
quality of life questionnaire for skin diseases, was used.4 However, according to the 
literature, quality of life scores correlate poorly with objective disease assessment.115, 116 
An objective scoring system should be able to reflect disease activity and treatment 
effect in a local region, even if another region has developed in another way. Another 
important aspect is the need for a more detailed score, since the majority of HS patients 
seeking help from dermatologists are cases graded as Hurley II, and within this group 
there is a wide variation of clinical findings and symptoms. Milder cases with com-
paratively small problems are in this group as well as the more severe cases that may 
have debilitating symptoms.  
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The earlier proposed version28 of the HSS has been used in at least three clinical 
treatment studies with TNF-alpha inhibitors. Fardet et al. evaluated seven severe HS-
patients prior to and after infliximab treatment.117 The score decreased by at least 40% 
in three patients. Ten HS patients were in another study treated with three infusions of 
infliximab and followed for one year.118 According to the authors, the HSS seems to be 
suitable for monitoring effects of treatment. They also found a good correlation be-
tween skin score and laboratory values and patient’s perception of disease activity. 
Further, they concluded that the score probably is too time-consuming for the routine 
patients but of value for research purposes or to decide whether a patient has severe 
enough HS to consider treatment with TNF-alpha inhibitors.118 In the third study, 10 
HS patients were treated with etanercept for 12 weeks.119 The disease activity was posi-
tively correlated with the HSS and more than 50% score improvement was found in six 
patients at week 12 and in seven patients at week 24.119 Negative experiences with HSS 
have also been reported. Brunasso et al. found “…the scoring system proposed by 
Sartorius et al which is very difficult to apply in severe HS as the lesions (comedones, 
nodules, fistulas and scars) tend to coalesce, making the numbers impossible to deter-
mine”.120 
In Paper I it was also attempted to use the score to illustrate a possible relationship be-
tween disease severity and tobacco smoking and obesity, respectively. Accumulating 
evidence indicates that smoking has negative effects on HS.1, 23 The group of non-
smoking patients in this study had significantly lower median HSS compared to the 
smokers, with the group who had stopped smoking in between. The DLQI did in that 
respect not discriminate the three groups. Overweight is another proposed risk factor.1, 
19 In this material, BMI was positively, but weakly, correlated to the HSS, and when 
divided in BMI-classes the obese group had higher median score values compared to 
the overweight patients, who in turn had higher medians compared to the normal 
weight patients. This was a trend for the material as a whole, as well as for the females, 
but not true for the men, perhaps due a rather small number of males included. As for 
smoking, the DLQI did not reveal any significant differences between the three weight 
groups, which suggest that a new scoring system is needed for such purposes.  
 
4.2 SCANNER-ASSISTED CO2-LASER SURGERY (PAPER II) 
The outcome of carbon dioxide (CO2) laser surgery with healing by secondary intention 
was retrospectively evaluated in 34 patients (31 women, 3 men) with mean age 33.9 
(range 15–55) years. One patient was lost to follow-up. The mean age at onset of 
disease was 22.3 (range 5–37) years. The areas treated varied from 5 to 50 cm² area in a 
total of 67 operating sites; one in 16, two in 10, three in two, four in four and five in 
two cases. A typical case is shown in Figure 11–12. The mean follow-up time was 34.5 
(range 7–87) months. The mean healing time was 4 (range 3–5) weeks. Four cases had 
had recurrence in a scar of one of the treated sites. The remaining patients had no recur-
rence in the treated regions, but in 12 patients new lesions or recurrences >5 cm away 
from the operation scars developed more than 8 months after surgery. Twenty-five pa-
tients had had recurrences of their hidradenitis suppurativa in an anatomical region 
different from the one that had been operated. Eight patients had had no apparent 
symptoms from their hidradenitis suppurativa during the follow up period (Table 2).  
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Figure 11 (a, b). CO2-laser treatment in the axilla of a patient with Hurley stage II HS. (a) Local 
anaesthesia is administered after delineating the lesions with ink. (b) CO2-laser vaporisation.  
 
 
Table 2. Number of reported recurrences at the time for follow-up (mean 34.5, range 7–87 
months) after scanner-assisted carbon dioxide laser treatment of 34 patients with hidradenitits 
suppurativa. 
 Number of recurrences 
None  8 
In operated areas  4 
In the same region but >5 cm from operated area  12 
In another anatomical area  25 
 
 
Postoperative course 
On a scale from 0 to 3, four patients classified their pain in the postoperative period as 
3 (made other activities impossible), fifteen as 2 (interfered with daily activities) nine as 
1 (did not interfere with daily activities) and six as 0. In our experience, the pain during 
care of the wound – i.e. changing the dressings – was the most difficult aspect of the 
postoperative course for these patients. After healing, at the time of interview, 31 pa-
tients considered that their condition was better than before surgery. Two patients 
considered that their illness had hardly changed and one patient stated it worse. The 
treated areas, which prior to surgery had been the most troublesome, had become a-
symptomatic, except in four cases. Although there was much postoperative scarring, 
the patients’ general and local functions were not impaired. All but one of them were 
pleased with the appearance of their scars after complete wound healing. One inguinal 
scar in a female patient was hypertrophic and had a 10 mm ulceration that healed after a 
single intralesional injection of steroids. Hospitalisation was not needed, but 
professional medical assistance for wound care was necessary in four cases. Only 
minor bleeding during cleaning of the wound was reported. There were no secondary 
infections. One had an episode of paresthesia in the arm lasting for 6 months after 
axillary surgery, and then subsided. Twenty patients were able to resume their regular 
job in less than 3 days. Four had to stop work for 4–8 days and ten for 2–3 weeks. 
Patients who had undergone other surgical methods for this condition preferred the 
(a) (b) 
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laser method and all patients except one would have accepted the same type of laser 
surgery again, if necessary.  
Carbon dioxide laser has previously been used in hidradenitis suppurativa surgery.97, 100 
Before scanner devices became available, a carbon dioxide laser operating at 30 W with 
a manually-controlled hand-piece was used that made the vaporisation very dependent 
of the surgeon’s experience.39, 99 The micro-processed optomechanical scanner system 
uses parallel mirrors to produce a fine spiral beam with an extremely short laser expo-
sure time, ablating tissue with a minimum of thermal injury.101, 121 When set at the 
continuous mode, the scanned laser beam drills downwards into the tissues and re-
moves the lesion rapidly in an even and controlled manner. This is providing an almost 
blood-less operating field which permits macroscopic examination of pathology of the 
tissue, early detection and minimal unintended damage of healthy or vascular tissues. 
Still, special caution is recommended in patients who have a low ratio of diseased 
skin/underlying healthy subcutaneous tissue, where the procedure is limited by muscu-
lar fascia or vital parts, i.e. nerves and blood vessels The main goal is to maintain a 
majority of the uninvolved tissue with appropriate surgical margins for radicality and 
thus provide a good chance of cure and yet leave a defect as small as possible. 
 
    
Figure 12 (a-d). Healing by secondary intention after carbon dioxide laser treatment (same 
patient as in Figure 11). (a) Immediately after, (b) 1 week, (c) 3 weeks, and (d) 3 months after 
CO2-laser surgery. 
 
 
The hypothesis underlying this surgical method is that radical removal and vaporisation 
of macroscopically active HS tissue will prevent recurrences. It is thought that if the 
epithelial sinuses, producing keratin and harbouring debris and bacteria, survive the 
treatment they can be the locus of recurrence. The scanner device has made the treat-
ment safer and less surgeon-dependent. Since 2006 a new laser (Unilas®10600 with 
SurgiScan®) that permits higher effect has been used in most cases, which permits 
faster treatment sessions. The clinical post-operative routine controls have in recent 
years been reduced to a wound control after one week and thereafter only when neces-
sary. 
There are limitations that should be noted in the interpretation of our study. Firstly, the 
out-patient files were analysed retrospectively and, in the follow-up, all patients were 
interviewed by telephone using a questionnaire. This information was therefore re-
ported by the patient. Secondly, our patients had been referred to us by other specialists, 
who had treated them unsuccessfully with other methods. Therefore we may have se-
(a) (b) (c) (d) 
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lected HS patients with a relatively more therapy resistant type of HS. Finally, our 
patients had Hurley stage II disease, which we regarded as operable with this method. 
Patients classified as Hurley III were referred to plastic surgeons for wide excision and 
reconstructive surgery. 
The carbon dioxide laser has also been used to excise HS.98 Excision techniques are 
essential in cases requiring pathological anatomic examination, e.g. to exclude sus-
pected squamous cell carcinoma. This method is also preferred in removal of larger 
amount of tissue in HS lesion and for Hurley stage III HS. Most patients seen in our 
Department of Dermatology have Hurley stage II and are not candidates for advanced 
major plastic surgery, although they suffer from a chronic disabling disease.3 Our re-
sults accord with those using other surgical methods,122, 123 and the need to repeat the 
treatment must be considered. Development of new abscesses outside symptomatic 
skin area cannot be prevented by any known surgical method and seem to indicate ac-
tivity of the underlying disease rather than a shortcoming of the method.122 In recurrent 
disease after carbon dioxide laser surgery, it should be treated again, if necessary, in 
conjunction with supplementary medical therapies. Recently, Hazen and Hazen de-
scribed the outcome of CO2-laser treatment of 61 patients with long-standing HS and, 
in most cases healing by secondary intention.103 A total of 185 areas were treated, in 
154 sessions (all but three of them in local anaesthesia), follow up after 1–19 years 
showed acceptable to excellent healing and only two recurrences in the 185 operated 
areas. The authors concluded that CO2-laser treatment appears to be an effective 
therapy for persistent HS, with good patient comfort, good healing and minimal risk of 
recurrence within treated areas.103 
 
4.3 BACTERAEMIA DURING CO2-LASER SURGERY OF HS (PAPER III) 
Blood samples for bacterial culture were obtained from 21 patients undergoing carbon 
dioxide laser surgery of HS; before, during and 10 minutes after operation. The total 
incidence of bacteraemia was 71%, i.e. bacteria in at least one sample (Table 3). Bacte-
rial growth in the first blood sample was found in nine patients, from the second in ten 
and from the third in six. Bacteria were detected in three samples from one patient. No 
microorganism was found in six of the 21 patients. 
 
 
Table 3. Incidence of bacteraemia before, during and 10 minutes after carbon dioxide laser sur-
gery of hidradenitis suppurativa. 
Sample Total number of bactaeremic patients (%) 
Before  9 (43) 
During   10 (48) 
10 min after  6 (29) 
Total  15 (71)* 
*Bacteria in at least one sample 
 
 
In total, 75 isolates were obtained from the samples collected before, during and after 
the surgical procedure. At least 12 bacterial species belonging to nine genera were 
identified (Table 4). The dominating group of bacteria was CoNS (29 isolates). Of 
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these, the species level of 18 strains was difficult to determine by conventional methods 
and these were therefore subjected to molecular typing. DNA sequence analysis 
showed that of the unidentified isolates 15 were Staphylococcus warneri and three were 
S. epidermidis/caprae. The other facultative anaerobic bacteria were alpha-streptococci 
and Enterococcus faecalis. Among the anaerobic isolates, Propionibacterium acnes and 
Propionibacterium granulosum were the most common bacteria. A few other anaer-
obes, like peptostreptococci, Eubacterium sp. and Veillonella, were also seen. 
Facultative anaerobic strains were more frequently isolated than anaerobic ones.  
 
 
Table 4. Microorganisms obtained from blood samples collected before, during and 10 minutes 
after carbon dioxide laser surgery for hidradenitis suppurativa. 
No. of patients from whom species were isolated in 
relation to the time of surgery (total colony count 
of species) 
 
Bacteria isolated  
Before (38a) During (19a) 10 min after (18a) 
    
Facultative anaerobic bacteria    
Staphylococcus warneri   4 (16)  3 (4)  3 (3) 
Staphylococcus epidermidis  1 (1)  3 (3)  1 (4) 
Staphylococcus sp.  2 (4)  1 (1)  3 (4) 
Micrococcus sp.  1 (1)  2 (2)  
Enterococcus faecalis  1 (1)   
Streptococcus sp.  1 (1)   
Corynebacterium sp.   1 (1)  
    
Anaerobic bacteria    
Propionibacterium acnes  4 (7)  4 (4)  1 (1) 
Propionibacterium granulosum  2 (5)  2 (2)  3 (6) 
Peptostreptococcus sp.  1 (1)  1 (1)  
Veillonella sp.  1 (1)   
Eubacterium sp.   1 (1)  
    
a Total colony count, all species 
 
 
In the literature, postoperative transient bacteraemia vary due to differences in the type 
of surgery and the method used for isolation of bacteria from blood. In the present 
study, the lysis-filtration technique with subsequent anaerobic incubation was used. The 
incidence and severity of bacteraemia were higher than those reported for other surgical 
procedures, which accords with previous studies of bacteraemia in various dental surgi-
cal procedures,110, 111 and supports the view that the combination of lysis-filtration and 
brain-heart infusion agar has very high sensitivity.111 Certain microorganisms requiring 
special conditions may not grow or survive in many common blood culture systems. 
Asymptomatic bacteraemia and a high frequency of contamination have been found 
with the use of blood culture systems based on the lysis of blood. Therefore, preopera-
tive blood samples have to be taken to estimate the true postoperative bacteraemia.111, 
124 
In six patients, all samples were negative which may suggest that the surgical method 
itself did not cause a spread of bacteria from the lesions. If it had, we assume that an 
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increase in the number of isolated microorganisms in the second sample, followed by a 
marked decrease of bacteria in the third, would have been found. Halpern et al. studied 
the incidence of transient bacteraemia in 45 patients undergoing skin surgery on the se-
baceous-rich areas of the head and neck. All their baseline blood culture results were 
negative, but three of them developed transient bacteraemia within the first 15 minutes 
after the start of the procedures.125 
The interpretation of blood cultures that are positive for CoNS or propionibacteria is 
often difficult. In the present study a surprisingly high number of positive preoperative 
samples were found, which may indicate a high frequency of contamination, compared 
to other studies using the same method in various oral surgical procedures.110, 111 On the 
other hand, the samples from healthy controls were negative, and all samples and cul-
tures were handled carefully under strict aseptic conditions to avoid contamination. It 
cannot be excluded that the surgical procedure itself may have had an effect on the 
patients which was not comparable to the conditions in the controls and this may have 
affected the contamination. Another possibility is that bacteria from the chronic lesions 
continually leak into the bloodstream of a subgroup of HS patients, and that they are 
detected with this very sensitive method of culture. This was an unexpected finding and 
more studies are needed for verification and to determine the clinical relevance. Our 
findings must be interpreted with caution; the number of patients was low and the 
patients were referred to us by other specialists, which may have selected patients with 
a relatively therapy-resistant HS. Further, our patients had Hurley stage II disease, and 
we have no data on bacteraemia in milder or more severe cases. Finally, the incidence 
of bacteria in the blood samples taken before surgery was high, which was the most 
surprising result of this study.  
The significance of bacteria in HS is disputed. Interpretation of the results of bacterio-
logical cultures from the surface of HS lesions is difficult because of possible 
contamination by the skin flora. The bacterial species found accorded with those of a 
previous study39 of deep cultures from HS lesions taken during CO2-laser vaporisation 
of the affected tissue to thereby minimise contamination, since the carbon dioxide laser 
permits heat sterilization.126-128 In that study, S. aureus and CoNS were the most fre-
quent, while Peptostreptococcus species and P. acnes were common as well.39 Maybe 
the findings in Paper III indicate a need to re-evaluate the significance of bacteria in the 
development of HS, and also the question if CoNS are true pathogens. It is known that 
foreign bodies increase the virulence of CoNS in surgical implants. A milieu which re-
sembles that produced by a foreign body, as found in chronic HS tissue, could increase 
the pathogenic properties of CoNS. In the present study, it is noteworthy that molecular 
typing of CoNS showed that 15 of 29 staphylococci isolates were S. warneri, which has 
been regarded as a contaminant, but more recently has become associated with signifi-
cant morbidity in infants at intensive care, where it has been isolated from subdural 
empyemas, urinary tract infections, osteomyelitis and bacteraemias.129, 130 Moreover, 
and perhaps of more relevance to HS; S. warneri has been found in chronic conditions 
associated with a foreign body.129, 130 These conditions resemble certain features of HS, 
as discussed above, but in our experience of almost 300 treated patients and from the 
literature, HS does not spread to other organs. However, it is customary to give pro-
phylactic preoperative antibiotic treatment regularly to HS patients with concomitant 
heart valve defects or immunodeficiency, but not to otherwise healthy ones. 
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4.4 PGP 9.5 DISTRIBUTION PATTERNS IN HS (PAPER IV) 
Skin biopsies from 16 HS patients of which 10 had inguinal and 6 had axillary 
involvement, were investigated both from lesions and perilesional location, and com-
pared to biopsies from 12 healthy matched controls. The intraepidermal nerve fibre 
profiles were distributed through the epidermis and most of them ran perpendicularly to 
the skin surface. In lesional skin there were a lower number of profiles in epidermis 
compared to controls. In the upper dermis, some PGP 9.5 positive nerve bundles were 
observed parallel to the epidermal-dermal junctional zone. In the middle and lower 
dermis, abundant nerves surrounded blood vessels, sweat glands, and hair follicles. 
Single PGP 9.5 positive cells were seen in the upper dermis in the healthy subjects 
whereas there were a substantial number of strongly fluorescent, spindle-shaped PGP 
9.5 positive cells in the dermal parts of the sections from lesional skin (Figure 13).  
 
4.4.1 Groin 
PGP 9.5 immunoreactive nerve fibre profiles  
The median (IQR) number of profiles/mm² in epidermis in patients was significantly 
lower than in controls, Table 5. On the contrary, the median (IQR) number of profiles 
in upper dermis was significantly higher in HS patients than in controls. In the middle 
and lower parts of dermis there were no significant differences in the number of nerve 
fibre profiles between patients and control subjects. In clinically non-involved skin 
from HS patients there was significant lower median number of profiles in epidermis, 
whereas in deep dermis there were a higher median number of profiles, compared to 
healthy controls. Comparison of lesional and non-involved skin from HS patients 
showed only one significant difference; a smaller median number of profiles from le-
sional skin in lower dermis (Table 5). 
 
    
Figure 13 (a, b). (a) Overview and (b) high magnification micrograph, of lesional skin from the 
groin of a HS patient, showing few nerve fibre profiles (arrows) in the epidermis, but a high 
number of PGP 9.5 positive cells (arrowhead) throughout the dermis. Bar equals 100µm. 
 
 
(a) (b)
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Table 5. PGP 9.5 positive nerve fibre profiles/mm² of the projected skin surface in lesional and 
clinically non-involved skin of the groin from HS patients, and groin skin from healthy con-
trols. Median values with interquartile range (IQR). Statistically significant differences from 
controls, defined as p-values < 0.05 (Mann-Whitney U-test), in bold. 
 
Control 
( 8=n ) 
Lesional 
( 10=n ) 
p-value 
 
Non-involved  
(n = 9) 
p-value 
 
Epidermis 181.5 (132–276)  45.5 (13–65) 0.0014  33 (8–53) 0.0079 
Upper dermis 174 (127–203)  802 (246–1439) 0.0434  420 (275–611) 0.0592 
Mid dermis 15.5 (6.5–126.5)  69.5 (13–169) 0.4598  90 (50–306) 0.0745 
Deep dermis 0 (0–26.5)  11.5 (0–26)* 0.3599  109 (49–225)* 0.0079 
*Statistically significant difference lesional – non-involved skin in HS patients, p = 0.0357 
(Wilcoxon matched pairs test) 
 
 
PGP 9.5 immunoreactive cells 
In epidermis there were no or few cells, without difference between patients and con-
trols. In all three dermal layers there were statistically significant higher median 
numbers of PGP 9.5 immunoreactive cells in lesional skin from hidradenitis suppura-
tiva patients compared to the healthy controls (Table 6 and Figure 13). There was no 
significant difference regarding median number of cells between non-involved skin 
from HS patients and controls. There was no difference between lesional and non-
involved skin from HS patients (Table 6). 
 
 
Table 6. PGP 9.5 positive cells/mm² of the projected skin surface in lesional and clinically non-
involved skin of the groin from HS patients, and groin skin from healthy controls. Median va-
lues with interquartile range (IQR). Statistically significant differences from controls, defined as 
p-values < 0.05 (Mann-Whitney U-test), in bold. 
 
Control 
( 8=n ) 
Lesional 
( 10=n ) 
p-value 
 
Non-involved  
(n = 9) 
p-value 
 
Epidermis 0 (0–0.5)  0 (0–1) 0.6334  5 (0–20) 0.1672 
Upper dermis 269.5 (207–362.5)  749 (394–1281) 0.0014  260 (113–557) 1.0 
Mid dermis 98.5 (59.5–126.5)  513.5 (282–1825) 0.0009  178 (42–350) 0.6058 
Deep dermis 23 (2–75.5)  339 (84–716) 0.0085  100 (28–550) 0.0745 
 
 
4.4.2 Axilla 
PGP 9.5 immunoreactive nerve fibre profiles  
Consistent with the findings in specimens from the groin, the median number of pro-
files/mm² in epidermis was lower in lesional skin from HS patients than in control skin, 
although the difference was not statistically significant. In all dermal layers there were 
significantly less profiles in lesional HS skin compared to control skin (Table 7, Figure 
14). Clinically non-involved perilesional skin from HS patients showed the same trend 
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as lesional skin compared to controls, however only significant in mid dermis. There 
was no difference between lesional and non-involved skin from HS patients (Table 7). 
 
 
Table 7. PGP 9.5 positive nerve fibre profiles/mm² of the projected skin surface in lesional and 
clinically non-involved skin of the axilla from HS patients, and axillary skin from healthy con-
trols. Median values with interquartile range (IQR). Statistically significant differences from 
controls, defined as p-values < 0.05 (Mann-Whitney U-test), in bold. 
 
Control 
( 4=n ) 
Lesional 
( 6=n ) 
p-value 
 
Non-involved  
( 6=n ) 
p-value 
 
Epidermis 98 (86–148)  4.5 (1–120) 0.2571  31 (1–114) 0.2571 
Upper dermis 475 (285–645)  133 (87–266) 0.0381  138.5 (73–191) 0.1714 
Mid dermis 196 (137.5–293.5)  12 (2–30) 0.0095  59 (25–86) 0.0381 
Deep dermis 128 (80.5–331.5)  8.5 (0–59) 0.0381  114 (81–124) 0.7619 
 
 
PGP 9.5 immunoreactive cells  
There were no statistically significant differences either between lesional skin and con-
trols, or between non-involved skin in HS patients and controls, regarding median 
number of PGP 9.5 positive cells in specimens from the axilla (Table 8). There were no 
or few PGP 9.5 positive cells in epidermis in lesional, clinically non-involved perile-
sional skin from HS patients and control skin (Figure 14). In dermis the trend was 
higher median numbers of PGP 9.5 positive cells in lesional skin compared to control 
skin specimens. There was only one significant difference between lesional and non-
involved skin from HS-patients; a higher median number of cells in mid dermis in 
lesional skin. 
 
 
Table 8. PGP 9.5 positive cells/mm² of the projected skin surface in lesional and clinically non-
involved skin of the axilla from HS patients, and axillary skin from healthy controls. Median 
values with interquartile range (IQR). There were no statistically significant differences be-
tween patients and controls, defined as p-values < 0.05 (Mann-Whitney U-test). 
 
Control 
( 4=n ) 
Lesional 
( 6=n ) 
p-value 
 
Non-involved  
( 6=n ) 
p-value 
 
Epidermis 0 (0–2)  0 (0–2) 0.9143  0 (0–0) 0.7619 
Upper dermis 238.5 (91.5–430)  451.5 (353–1570) 0.2571 202 (175–555) 0.6095 
Mid dermis 134.5 (119.5–732)  1528 (193–2102)* 0.2571 213 (66–582)* 0.6095 
Deep dermis 55 (21.5–336)  1084 (59–1965) 0.1714 269.5 (77–490) 0.6095 
*Statistically significant difference lesional – non-involved skin in HS patients, p = 0.028 (Wil-
coxon matched pairs test) 
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Figure 14 (a,b). (a) Skin from the axilla of a healthy control, with vertical nerve fibre profiles 
(arrow) in the epidermis and an overall low number of PGP 9.5 positive cells. (b) Lesional skin 
from the axilla of a HS patient, with few nerve fibre profiles (arrows) in the epidermis, median 
number of profiles in dermis and some PGP 9.5 positive cells (arrowheads) in dermis. Bar 
equals 100 µm. 
 
 
Indirectly, the neuroendocrine involvement in HS could be studied through investiga-
tions of therapeutic effects. However, only two studies were found in the literature of 
treatment for HS-patients with the primary focus to influence the neuroendocrine sys-
tem. First, a fertile woman with severe familial HS was given a combination of 
dexamethasone and a synthetic gonadotropin releasing hormone agonist.131 The patient 
was reported to improve at the same time as her adrenals and ovarians were suppressed, 
as indicated by blood level changes of testosterone, dehydroepiandrosterone sulphate, 
androstendione and estradiol.131 Second, Bogers et al. described a HS-patient with 
premenstrual exacerbations, who was improved after hysterectomy and bilateral 
salpingo-oophorectomy combined with estrogen substitution. Prior to ectomias, some 
improvement was noticed after treatment with a gonadotropin-releasing hormone 
agonist followed by a gonadotropin-releasing hormone agonist together with estrogen 
substitution.132 
A number of studies performed on other inflammatory skin diseases, e.g. atopic derma-
titis,66, 67 contact dermatitis68 and psoriasis,64 show increased as well as decreased levels 
of neuroendocrine markers, including PGP 9.5. In particular, a recent study found a de-
creased number of epidermal PGP 9.5 immunoreactive nerve fibres in involved 
psoriatic skin during exacerbation.69 To our knowledge, this is the first study of PGP 
9.5 distribution in HS. 
In both the groin and axilla it was noticed that the median number of profiles in epi-
dermis from patients was lower, however not significant in the axilla, compared to 
normal skin. Contradictory findings were obtained regarding profiles in dermis, where 
there was an increased number of profiles in upper dermis of the groin in the patients, 
whereas in the axilla the lesional dermal skin contained significantly fewer profiles 
compared to healthy controls. Although the number of study subjects was limited, the 
biopsies were analysed separately according to localisation (groin and axilla, respec-
tively), since previous studies have shown difference in innervation density between 
certain human skin areas body parts.133 
 
(a) (b)
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Further, the number of PGP 9.5 positive cells was quantified, but only cells with strong 
fluorescence were counted, while melanocytes and other weak fluorescent cells in epi-
dermis were not. In normal skin sparse, single, fluorescent dendritic cells were seen in 
upper dermis. In lesional skin, a large number of PGP 9.5 positive cells, mostly spindle-
shaped, were noted throughout the dermis although not statistically significant in the 
axilla, maybe due to a too small number of samples. The origin of the PGP 9.5 positive 
cells was not further investigated in this study, but there are several candidates 
including fibroblasts, macrophages, and dendritic cells.134 The study has several limita-
tions. One is that the biopsies were taken from HS patients with probably different 
duration of the lesions. Another is that due to the small number of study subjects, no 
analysis of subgroups, e.g. gender, smoking habits, body weight, et cetera could be 
done. No investigation of the stress level was performed. Biopsies from patients were 
taken from clinically non-involved skin as well as involved, but for practical reasons 
the non-involved skin biopsies were taken relatively close to the lesions (approximately 
2 cm perilesionally). We have not been able to explain the reasons behind the discrep-
ancy and opposing results for dermal PGP 9.5 profiles in the axilla compared to the 
groin, in connection with lesional skin versus control skin. However, different results of 
nerve fibre density are often found in skin from various anatomical regions, especially 
when the regions are as far apart as the axilla and the groin,133 although in our clinical 
experience, HS has the same characteristics and behaviour in both regions.  
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5 CONCLUSIONS 
The main findings in Paper I were that HSS was positively correlated to Hurley stage, 
to smoking and obesity and fairly good correlated to DLQI. This indicates that the HSS 
reflects disease severity and brings out relevant information from a HS patient material. 
HSS has after modification and simplification of the preliminary version,28 become 
more practical to perform, and a patient can be scored in about 5 minutes, depending on 
the extent of the disease. The HSS is primarily designed for clinicians especially inte-
rested in HS. HSS may be suitable as a scoring method in clinical trials since it 
correlates with existing scores and potential risk factors, suggesting that it reflects a 
valid estimation of disease severity. 
The results in Paper II indicate that in patients with chronic HS of Hurley grade II, mac-
roscopically controlled, tissue selective and skin preserving scanner-assisted carbon 
dioxide laser treatment of selected affected areas followed by secondary intention 
healing, is a safe and rapid surgical method with satisfactory cosmetic and functional 
results and low recurrence rate, suitable for out-patients.  
In Paper III, it was concluded that the carbon dioxide laser vaporisation treatment of 
HS did not seem to cause any additional spread of bacteria into the bloodstream. The 
evaluation of cultures containing microorganisms from normal skin flora is always 
controversial. Since the bacteria detected in this study accord with those obtained pre-
viously in cultures from deeper parts of HS lesions,39 they seem to be relevant. The 
results should be interpreted with caution; however, growth of bacteria in the first blood 
sample taken before surgery could indicate that some of these patients have bacteria 
continuously circulating in the blood. Therefore more and larger studies should be done 
in HS patients.  
An imbalance of the PGP 9.5 immunoreactive nerve fibre profiles and PGP 9.5 positive 
cells by immunohistochemical staining, compared to controls, is demonstrated in Paper 
IV. In conclusion, despite several study limitations, the findings indicate that PGP 9.5 
positive nerve fibres could be involved in the pathogenesis of HS. The functions of the 
nerve fibres and the PGP 9.5 positive cells are not known. Both regarding the profiles 
and the cells, further studies must be made to show if these differences are primary 
events, or secondary to, for example, chronic inflammation, which is considered a ma-
jor issue of HS. In addition, the origin of the cells needs to be further investigated.  
HS patients have a high degree of morbidity as measured by the DLQI. To evaluate this 
in an objective manner, in addition to the established Hurley staging system, a new 
clinical score has been proposed and is shown to correlate both to other scores and to 
HS risk factors. Treatment by carbon dioxide laser seems to give satisfactory results 
and is not shown to spread bacteria during treatment sessions. Involvement of bacteria 
in HS is disputed, and the knowledge is limited. This is true also for other pathogenic 
mechanisms. The presence and role of neuroendocrine-immune system elements such 
as nerve fibre profiles and cells remain to be further mapped and investigated in HS.  
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6 PERSPECTIVES 
6.1 BACTERIOLOGY 
The presence of bacteria, especially CoNS, in deeper parts of chronic HS lesions inves-
tigated in a previous study, indicate pathogenic relevance, but whether a primary or 
secondary event is not known.39 In another study it was found that the patients in whom 
Staphylococcus. aureus was found had a shorter duration of disease, why it was sug-
gested that S. aureus may play a temporary role in the early phase of the disease.135 
This issue is investigated in an ongoing study, where we examine and treat patients 
with acute nodules or abscesses, and bacterial culture is performed before and during 
carbon dioxide laser vaporisation. Samples are taken from the skin surface and then 
from the deeper layer of the lesions. At each level two samples are taken, one with a 
punch biopsy technique and one by pressing a soft agar gel against the skin. 
 
6.2 THE NEUROENDOCRINE SYSTEM  
The skin is obviously an easily accessible organ system for investigating the peripheral 
effects and production of stress mediators, and subsequently gives insights into neuro-
endocrine-immune dysfunctions. From the growing knowledge about the brain-skin 
connection, it is known that numerous neurotransmitters, neuropeptides, neurotrophins 
and neurohormones are present locally and act as both major targets and effector mes-
sengers of the stress response.53, 136 Evidence of neuroendocrine involvement in HS is 
as yet sparse, but there are parallels to other inflammatory skin diseases, where various 
immunoreactive cells are known to be active, and from which hypotheses of HS 
pathogenesis can be generated.  
Other conditions where PGP 9.5 have been investigated include cutaneous squamous 
cell cancer and keratoacanthomas, where cytoplasmic PGP 9.5 staining was associated 
with tumour aggressiveness.137 In another recent publication, investigation of 
intraepidermal nerve fibre density at wrist level in diabetic and non-diabetic patients 
with mild neuropathy showed no difference between diabetic and non-diabetic patients, 
but higher nerve fibre density in hairy skin compared with glabrous skin and higher in 
females than in males.138 In one study, the effect of acute stress on Langerhans’cells 
(LC) and cutaneous nerve fibre expression of PGP 9.5 and calcitonin-gene related pep-
tide (CGRP) measured in healthy volunteers, showed reduction of LC and CGRP, 
while PGP 9.5 was increased, after the stress exposure.139 
The next step of our team in the investigation of neuropeptides in HS is to employ 
double-staining for PGP 9.5 and various neuro-immune markers; including nerve 
growth factor (NGF), substance P (SP), calcitonin gene related peptide (CGRP) and 
tryptase. 
 
6.3 TREATMENT 
It would appear that definitive treatment consists mainly of surgery, while pharmaceu-
ticals mainly serve as adjunct therapy, although recently both tumour necrosis factor-
alpha inhibitors and the combination of rifampicin and clindamycin have been shown 
to induce long-term remission in open case-series.30, 75, 119, 140-143 Recently a RCT of 
infliximab has shown the drug to have significant effect in HS, which is in good agree-
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ment with 34 earlier publications reporting generally positive outcomes in cases or 
open series, with altogether 105 HS patients treated with tumour necrosis factor-alpha 
inhibitors.88, 144 Tierney et al. evaluated the effect of an epilating Nd:YAG-laser in a 
randomised controlled study of 22 HS patients with a significant improvement com-
pared to control treatment (topical antibiotic).145 The results are in line with the 
follicular pathogenic hypothesis. 
The main potential side effect of long-term antibiotic treatment is that the equilibrium 
between host and microorganisms may be disturbed by the use of antibiotic therapy. 
Antimicrobial resistance is a growing problem and is associated with clinical use of an-
tibiotics, since a balanced microflora prevents establishment of resistant strains of 
bacteria.38, 146 Antibiotic treatment for three months or more seems to be necessary in 
HS. Long-term treatment with antibiotics can develop, for example, resistant Propioni-
bacterium acnes and CoNS of the skin.38 Topical Clindamycin could increase carriage 
of resistant P. acnes and Staphylocccus epidermidis, and there could be a risk of trans-
fer to other pathogenic bacteria like Staphylococcus aureus and Streptococci.38, 147 For 
acne cases it is recommended to combine antibiotics with benzoyl peroxide to reduce 
the risk of resistant strains of especially P. acnes.148  
A target for topical therapy, preferably in the early phase, is the follicular hyper kerati-
nisation, and empirically different acne preparations have been tried. Although not 
formally studied in HS, azelaic acid cream has been used, in monotherapy or together 
with topical clindamycin, with improvement, especially in mild cases.71 Azelaic acid 
cream can also serve as adjunct therapy when surgery is planned. A personal 
observation is that some of the patients even achieve control over the disease after long 
term use, perhaps in addition to having reduced or stopped smoking. This observation 
needs to be investigated systematically.  
At our department, CO2-laser vaporisation has been the treatment of choice in patients 
with Hurley stage II HS. If the area that needs to be removed is large, a combination 
technique where the body of the lesion is debulked by cutting electrosurgery, with sub-
sequent vaporisation of the margins to achieve radicality, is used. CO2-laser treatment 
can sometimes be a complement to advanced plastic surgery in cases where a smaller 
loco regional recurrence develops in the excision margins. Finally, since the scanner-
assisted CO2-laser vaporisation is a safe and relatively fast treatment method suitable 
for outpatients, it could be considered a first line treatment for acute exacerbations of 
inflamed nodules as a definitive alternative to short-term solutions such as lancing. 
 
6.4 ASSOCIATED CONDITIONS 
6.4.1 Obesity 
It is speculated that overweight and obesity may aggravate HS. Analogies from psoria-
sis, where a higher prevalence of obesity, hypertension and dyslipidemia has been 
shown in patients,149 could suggest a potentially causal relationship between parts of the 
metabolic syndrome and chronic cutaneous inflammation, which could be of impor-
tance in the pathogenesis of HS. In our material as well as in other studies, HS patients 
are on average overweight, but not all of them are and little is known about other parts 
of the metabolic syndrome in HS. Potentially, HS patients may benefit from additional 
metabolic interventions, and increased knowledge in this field could contribute to 
development of targeted therapy. Participation in a Nordic multicentre study of HS 
   34
patients and controls regarding the prevalence of obesity and the metabolic syndrome is 
in the planning stage. 
 
6.4.2 Smoking 
Accumulating observations of the fact that smokers are overrepresented in HS can still 
not determine if this is a causal relationship or a parallel phenomenon. This needs to be 
further explored, for instance through studies of the nicotinic receptor in skin biopsies, 
in analogy to the imbalance found in pustulosis palmoplantaris,150 and in the above 
mentioned study of acetylcholine receptors in HS.35 Anecdotally, a number of patients 
have reported improvement after having reduced or stopped smoking, and in a recent 
publication, remission of HS is reported in two cases.151 A clinical interventional study 
of tobacco cessation would also be of great importance.  
 
6.4.3 Psychological morbidity 
It is well known that HS causes a high degree of morbidity, and that the patients 
experience lower life quality, but so far the number of publications exploring the 
psychological load and the prevalence of psychiatric diseases like depression in asso-
ciation with HS are few. Therefore it would add valuable information to set up studies; 
both large epidemiological and more elaborate investigations of psychic health in 
smaller series of individual cases. Collaboration with the Psychology Department of 
Stockholm University is in progress, where HS patients are invited to participate in a 
detailed interview that intends to depict the patient’s perception of the disease, and 
where appropriate psychological tests of stress, anxiety or depression can be made.  
 
6.5 SCORING 
6.5.1 Reliability 
The new system for scoring disease severity, HSS, is shown to correlate with other 
scores and suspected risk factors, in Paper I as well as in a study by Canoui-Poitrine et 
al., who used the by Revuz152 modified HSS in 302 French HS patients.10 It was con-
cluded that the score, although not formally validated, was highly correlated with 
Hurley stage and intensity and duration of pain as well as suppuration.10 Another 
important issue is the reliability of the tool, which can be investigated by measuring the 
interobserver variability when scoring the same set of patients. This has recently been 
performed in 23 HS patients, by four observers, and showed a high factor of concor-
dance (0.95) and low interobserver variability (Sartorius et al., in press).  
 
6.5.2 HSS used in clinical studies 
The earlier proposed version and modifications of the HSS have been used in a number 
of studies which are summarized in Table 9. The majority of these studies were pub-
lished independently of our group. Therapies that have been evaluated include TNF-α 
inhibitor therapy,117-119, 153-155 photodynamic therapy,156 RCT of neodymium-doped 
yttrium aluminium garnet laser,145 and clindamycin and rifampicin in combination 
therapy.74  
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Table 9. Published studies where HSS including modified versions has been used 
First author (year) n Pre-scorea Post-scorea Treatment Comment 
Treatment studies      
Sartorius (2003)28 
 
 34 30.5 ± 24.2 12.0 ± 17.2 CO2-laser Total score, n = 29 for 
evaluation 
Fardet (2007)117 
 
 7 82 ± 30 NA Infliximab Score decreased 40% 
in 3 patients 
Mekkes (2008)118 
 
 10 164 ± 50 89 ± 49  Infliximab 1 year 
Giamarellos-
Bourboulis (2008)119 
 10 278b 114b Etanercept 24 weeks 
Pelekanou (2009)153  10 124.8c NA Etanercept Long-term follow up 
of study33 above 
Sotiriou (2009)156  5 18.8  17.2 PDT Regional score,  
2 months 
Sotiriou (2009)154  4 25d 18d Etanercept 3 months after 
treatment 
Sotiriou (2009)155  3 24.3 16.6 Adalilumab 3 months after 
treatment 
Gener (2009)74  116 29 (14.5) 14.5 (11) Clindamycin 
+Rifampicin 
n = 70 for evaluation  
Tierney (2009)145 
Control 
 22 29.8 ± 13.5 
28.3 ± 13 
9.7 ± 6.2 
24.3 ± 10.8 
Nd:YAG-laser 
RCT 
All sites combined. 
Modified scoree  
Other studies      
Wolkenstein (2007)4 
 
 61 25.1 ± 18.2 NA - Quality of life study 
Canoui-Poitrine 
(2009)10 
 302 17 (16) NA - Clinical characteris-
tics and risk factors 
Sartorius (2009, Paper 
I) 
 115 38 (18–66) NA - Clinical characteris-
tics and risk factors 
Sartorius (2010, 
accepted) 
 61 40 (18–73) NA - Interobserver 
variability n = 23  
a before and after treatment; mean if single value, mean ± SD or median with interquartile range 
(IQR); b–d approximated means from b Giamarellos-Bourboulis (2008)119; c Pelekanou (2009)153; 
d Sotiriou (2009)154; e points added for erythema, edema, pain, purulent discharge; NA, not 
applicable; RCT, randomized controlled trial 
 
 
6.5.3 Further development of the score 
There are some limitations in the use of HSS. Firstly, we have noticed that for the most 
severe cases, with widespread disease that affects large skin areas, the difficulty to 
determine HSS increases, since it is hard to define single lesions if they are coalescing. 
Secondly, the degree of inflammation of individual lesions, or regions, is not included 
in the score, which would be valuable in particular for descriptive studies or studies of 
non-surgical therapy. Over time, in the same patient, the grade of inflammation can 
vary a lot, from silent periods with relatively dry sinus openings, no erythema and non 
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inflamed nodules to flare-up periods with pronounced erythema, oedema, suppuration 
and painful inflamed nodules. Thirdly, for some cases there are difficulties to 
distinguish between a small fistula and a large nodulus. This is important for the total 
score since a fistula renders six points and a nodulus only one. Finally, subjective 
variables are not included in the total score. Since pain is a major feature of HS it can 
be added as grading the worst lesion chosen by the patient using a visual analogue 
scale. DLQI or another subjective scoring system of life quality is suggested to be used 
in complement to HSS in future prospective trials. Work is in progress in a European 
network of dermatologists with special interest and expertise in HS to further improve 
the assessment of HS severity, especially treatment effects.  
 
6.5.4 Hidradenitis suppurativa registry 
A Nordic HS registry is under development, with the purpose to collect clinical and 
basic epidemiological facts about HS patients, to enable evaluation of medical and 
surgical treatment effects in individual patients, and also to collect a cohort which can 
be followed over a long period of time. When appropriate, it would become a basis for 
epidemiological HS research. In addition a common Nordic registry enables the use of 
uniform reporting of outcome variables and side effects in multicentre clinical trials. 
 
6.6 FINAL REMARKS 
Improved knowledge of the mechanisms that drive the pathogenesis in HS will lead to 
a better understanding of this disease and shed light on what may be the critical role of 
the immune system together with the function of keratinocytes. Future developments 
aimed at the etiological mechanisms could provide new targeted opportunities to amend 
the therapeutic arsenal available to deal with HS. Early treatment and careful 
management could then further improve the outcome and quality of life for patients 
with HS. 
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7 SUMMARY IN SWEDISH 
Hidradenitis suppurativa (HS) är en kronisk inflammatorisk hudsjukdom med okänd 
orsak, även om en del mekanismer i sjukdomsutvecklingen är kända. HS yttrar sig som 
smärtsamma knölar (noduli) och bölder samt i senare stadier även ärrbildning och 
fistelgångar. Sjukdomen är lokaliserad till områden med terminala hårfolliklar och 
apokrina körtlar som armhålor, ljumskar, anogenitalt, på klinkor och under bröst. HS 
börjar i allmänhet efter puberteten, oftast i 20-årsåldern, och kan pågå i många år. 
Sjukdomen förekommer i högre utsträckning hos kvinnor än hos män. Bland 
riskfaktorer för HS finns rökning och övervikt. Botande behandling består främst av 
kirurgi, men det finns olika medicinska behandlingar som passar i lindriga fall och även 
när kirurgi är olämpligt eller när man behöver kompletterande behandling. 
Lokalbehandling med antiinflammatorisk eller antibiotikainnehållande kräm/emulsion, 
kortisoninjektioner, långtidsbehandling med perorala antibiotika, eller i svåra fall 
immunmodulerande läkemedel finns bland de behandlingar som ges. För medelsvår HS 
(med en eller flera åtskilda och återkommande bölder med fistel- och ärrbildning) 
används ibland en kirurgisk behandling med koldioxidlaser, där man med scannerstödd 
teknik förångar sjuk vävnad, lager för lager, och därefter vanligtvis lämnar såren öppna 
för så kallad sekundärläkning. Metoden lämpar sig för öppenvård och den teknik som 
nu används har gjort metoden säkrare och mindre operatörsberoende än tidigare använd 
frihandsteknik. 
I denna avhandling har olika kliniska aspekter av HS studerats: utveckling av ett 
kliniskt utvärderingsinstrument för bedömning av svårighetsgrad (hidradenitis 
suppurativa score, HSS), utvärdering av kirurgisk behandling med koldioxidlaser, 
förekomsten av bakterier i blodet hos HS-patienter och slutligen förekomst och 
utbredning av den neuroendokrina markören PGP (protein gene product) 9.5 i 
hudbiopsier. 
I delarbete I var syftet att undersöka den nu förenklade kliniska mätmetoden HSS, där 
HS-förändringar räknas och poängsätts, samt studera om BMI (body mass index) 
respektive rökning påverkar sjukdomsgraden. Ett frågeformulär angående livskvalitet 
vid hudsjukdom, Dermatology life quality index (DLQI) fylldes i av 246 patienter, och 
115 bedömdes enligt HSS. Undersökningen visade att det fanns ett visst positivt 
samband mellan HSS och DLQI och att patienter med högre sjukdomsgrad hade 
signifikant högre HSS. Likaså hade rökare högre HSS än icke-rökare och kraftigt 
överviktiga kvinnor högre HSS än normalviktiga, vilket inte kunde visas hos männen 
(som i studien var färre). Resultaten talar för att HSS avspeglar svårighetsgrad och 
samvarierar med riskfaktorer samt att det förefaller lämpat för kliniska prövningar. 
Delarbete II handlar om resultaten efter koldioxidlaserkirurgi med efterföljande 
sekundärläkning hos 34 HS-patienter, med totalt 67 operationsområden. Patienterna 
intervjuades per telefon angående läkningsförlopp, ärrbildning, funktion samt 
sjukdomsaktivitet respektive återfall efter behandlingen. Fyra patienter hade fått återfall 
av HS i ett operationsområde. Tolv hade fått nya HS-förändringar > 5 cm från op-
området och 25 hade haft uppblossning av HS i en annan kroppsregion. Åtta patienter 
hade varit helt besvärsfria sedan operationen. Medellängd för läkningstid av såren var 4 
veckor. De kirurgiska resultaten var tillfredsställande med avseende på ärrbildning och 
funktion. 
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I delarbete III utfördes blododlingar på 21 HS-patienter med medelsvår sjukdomsgrad, 
före, under samt efter operation med koldioxidlaser. I första provet fann man 
bakterieväxt hos nio av dessa, i andra provet hos tio och i tredje provet hos sex 
patienter. En patient hade bakterieväxt i alla tre proverna. Flera olika sorters bakterier 
odlades fram, varav koagulasnegativa stafylokocker var vanligast. Odlingarna hos sex 
av patienterna var genomgående negativa, vilket kan tyda på att själva 
operationsmetoden inte orsakar bakteriespridning till blodet. 
Delarbete IV beskriver förekomst och utbredning av nervfibermarkören PGP 9.5 i 
hudbiopsier från 16 HS-patienter. Biopsierna delades upp i två grupper beroende på 
provlokal; ljumske respektive armhåla, och undersöktes med immunhistokemisk teknik 
i mikroskop, varvid man fann att medianantal nervprofiler (de nervdelar som räknades) 
var lägre i överhud hos sjuka, jämfört med kontroller. I läderhuden var det 
motsägelsefulla resultat; en ökning av medianen i ljumskar men en minskning i 
armhålegruppen. Även PGP 9.5-positiva celler räknades, och man såg en ökning i sjuk 
läderhud, där skillnaden ljumskgruppen var signifikant. Cellerna har ännu inte 
undersökts närmare med avseende på typ. 
HS-patienter upplever en hög sjukdomsbörda och rejält sänkt livskvalitet enligt mät-
ningar med DLQI. För att även få ett objektivt mått att följa, t ex för att utvärdera 
behandlingsresultat, har ett kliniskt poängsystem (HSS) utvecklats och visat sig 
korrelera både till andra utvärderingsmetoder och till riskfaktorerna rökning och 
övervikt. Koldioxidlaserkirurgisk behandling verkar ge tillfredsställande resultat och 
inte sprida bakterier under behandlingen. Kunskapen om sjukdomsorsakerna är 
fortfarande begränsad, och betydelsen av bakterier liksom även nervfiberprofiler och 
celler från det så kallade neuroendokrin-immuna systemet, i HS-förändringar är oklar. 
Ökad kunskap om sjukdomsmekanismer skulle kunna leda till utveckling av förbättrade 
behandlingsmetoder som riktar in sig mer direkt på orsakerna till HS. Det är dock 
oavsett metod viktigt med en tidig och korrekt diagnos som kan ligga till grund för 
behandling, med syfte att uppnå bästa möjliga resultat och därmed öka livskvaliteten 
för de människor som drabbas av HS. 
   
  
39
8 ACKNOWLEDGEMENTS 
These studies were done in the Department of Dermatology and Venereology at Karo-
linska University Hospital (former Huddinge University Hospital). Many people have 
in different ways supported the work on this thesis. In particular, I would like to express 
my sincere gratitude to the following: 
Lennart Emtestam, my supervisor, for excellent scientific guidance, endless enthusi-
asm, encouragement, trust and generous support. 
Jan Lapins, my co-supervisor, for great generosity in sharing an immense clinical 
experience of hidradenitis suppurativa, and excellent scientific guidance. 
Gregor Jemec, my co-supervisor, for excellent scientific guidance and cheerful encour-
agement. 
Åsa Boström, head of the Department of Dermatology and Venereology, Södersjuk-
huset (my present employer), for generous support in the completing phase of the 
thesis. 
Lena Lundeberg, Harry Beitner and Peter Lidbrink, head and former heads of the 
Department of Dermatology and Venereology, Karolinska University Hospital 
respective Huddinge University Hospital (employer from 2000 to August 2009), for 
generous support through the years. 
Shah Jalal, Maria Hedberg, and Olle Johansson, my co-authors, for fruitful collabora-
tion. 
Gun-Britt Karlberg and Marianne Ekman, for excellent technical assistance. 
All patients and volunteers, for generous cooperation and time. 
Maria Gossart, Eva Björnelius, Lena Hagströmer, Natalia Kuzmina, Cristina Oprica, 
Miruna Nyrén, Toomas Talme, Jan Eklind, Martin Hall and Hassan Killasli, my former 
colleagues at the Department of Dermatology and Venereology, Huddinge, for stimu-
lating discussions and cheerful encouragement; Barbro Andersén, Ansi Lindberg and 
Annika Johansson, for excellent clinical assistance; Susanna Lidman and Gerda 
Bergström for administrative assistance and general support. 
All colleagues and staff not mentioned above, at the Department of Dermatology and 
Venereology at Karolinska Huddinge and Solna, and at Södersjukhuset, for generous 
support, for sharing knowledge and skills, and for creating a good atmosphere at work. 
Elisabeth Berg and Margareta Krook-Brandt, LIME, KI, for statistical advice. 
The Department of Medicine, Huddinge, for helpfulness during the postgraduate edu-
cation.  
The Department of Photography, for photographic skills. 
Lars Hörngren, for linguistic revision. 
Family and friends, for support and encouragement. 
Last, but by no means least: Patrik, my husband, and Martin, Jonas and Emil, our sons, 
for love and trust. 
The research was supported by grants from Stockholm City Council, Swedish Society 
of Medicine, Karolinska Institutet, Edward Welander Foundation for Medical Re-
search, Swedish Cancer & Allergy Foundation and the Finsen Foundation. 
   40
9 REFERENCES 
1. Kurzen H, Kurokawa I, Jemec GB, Emtestam L, Sellheyer K, Giamarellos-
Bourboulis EJ, et al. What causes hidradenitis suppurativa? Exp Dermatol 
2008; 17:455-6; discussion 7-72. 
2. Jansen T, Plewig G. Acne inversa. Int J Dermatol 1998; 37:96-100. 
3. Jemec GB, Heidenheim M, Nielsen NH. Hidradenitis suppurativa--
characteristics and consequences. Clin Exp Dermatol 1996; 21:419-23. 
4. Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J. Quality of life 
impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad 
Dermatol 2007; 56:621-3. 
5. von der Werth JM, Jemec GB. Morbidity in patients with hidradenitis 
suppurativa. Br J Dermatol 2001; 144:809-13. 
6. Tilles G. Verneuil and Verneuil's disease: an historical overview. In: Jemec 
GBE, Revuz J, Leyden J, editors. Hidradenitis Suppurativa. Berlin Heidelberg 
New York: Springer; 2006. p. 4-10. 
7. Yu CC, Cook MG. Hidradenitis suppurativa: a disease of follicular epithelium, 
rather than apocrine glands. Br J Dermatol 1990; 122:763-9. 
8. Attanoos RL, Appleton MA, Douglas-Jones AG. The pathogenesis of 
hidradenitis suppurativa: a closer look at apocrine and apoeccrine glands. Br J 
Dermatol 1995; 133:254-8. 
9. Jemec GB, Hansen U. Histology of hidradenitis suppurativa. J Am Acad 
Dermatol 1996; 34:994-9. 
10. Canoui-Poitrine F, Revuz JE, Wolkenstein P, Viallette C, Gabison G, Pouget F, 
et al. Clinical characteristics of a series of 302 French patients with hidradenitis 
suppurativa, with an analysis of factors associated with disease severity. J Am 
Acad Dermatol 2009; 61:51-7. 
11. Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2009; 
23:985-98. 
12. Jemec GB. Hidradenitis suppurativa. J Cutan Med Surg 2003; 7:47-56. 
13. Poli F, Jemec GBE, Revuz J. Clinical presentation. In: Jemec GBE, Revuz J, 
Leyden J, editors. Hidradenitis Suppurativa. Berlin Heidelberg New York: 
Springer; 2006. p. 11-24. 
14. Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis 
suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996; 
35:191-4. 
15. Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, 
et al. Prevalence and factors associated with hidradenitis suppurativa: results 
from two case-control studies. J Am Acad Dermatol 2008; 59:596-601. 
16. von der Werth JM, Williams HC. The natural history of hidradenitis 
suppurativa. J Eur Acad Dermatol Venereol 2000; 14:389-92. 
17. Palmer RA, Keefe M. Early-onset hidradenitis suppurativa. Clin Exp Dermatol 
2001; 26:501-3. 
18. Naldi L. Epidemiology. In: Jemec GBE, Revuz J, Leyden J, editors. 
Hidradenitis Suppurativa. Berlin Heidelberg New York: Springer 2006. p. 58-
64. 
19. Barth JH, Layton AM, Cunliffe WJ. Endocrine factors in pre- and 
postmenopausal women with hidradenitis suppurativa. Br J Dermatol 1996; 
134:1057-9. 
20. Von Der Werth JM, Williams HC, Raeburn JA. The clinical genetics of 
hidradenitis suppurativa revisited. Br J Dermatol 2000; 142:947-53. 
   
  
41
21. Gao M, Wang PG, Cui Y, Yang S, Zhang YH, Lin D, et al. Inversa acne 
(hidradenitis suppurativa): a case report and identification of the locus at 
chromosome 1p21.1-1q25.3. J Invest Dermatol 2006; 126:1302-6. 
22. Jemec GB. The symptomatology of hidradenitis suppurativa in women. Br J 
Dermatol 1988; 119:345-50. 
23. König A, Lehmann C, Rompel R, Happle R. Cigarette smoking as a triggering 
factor of hidradenitis suppurativa. Dermatology 1999; 198:261-4. 
24. Morgan WP, Leicester G. The role of depilation and deodorants in hidradenitis 
suppurativa. Arch Dermatol 1982; 118:101-2. 
25. Chren MM. Giving "scale" new meaning in dermatology: measurement matters. 
Arch Dermatol 2000; 136:788-90. 
26. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple 
practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210-6. 
27. Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis 
suppurativa and familial benign pemphigus. Surgical approach. In: Roenigk 
RK, Roenigk Jr HH, editors. Dermatologic surgery. Principles and practice. 
second ed. New York: Marcel Dekker; 1996. p. 623-45. 
28. Sartorius K, Lapins J, Emtestam L, Jemec GB. Suggestions for uniform 
outcome variables when reporting treatment effects in hidradenitis suppurativa. 
Br J Dermatol 2003; 149:211-3. 
29. Boer J, Weltevreden EF. Hidradenitis suppurativa or acne inversa. A 
clinicopathological study of early lesions. Br J Dermatol 1996; 135:721-5. 
30. Jansen I, Altmeyer P, Piewig G. Acne inversa (alias hidradenitis suppurativa). J 
Eur Acad Dermatol Venereol 2001; 15:532-40. 
31. Kurzen H, Jung EG, Hartschuh W, Moll I, Franke WW, Moll R. Forms of 
epithelial differentiation of draining sinus in acne inversa (hidradenitis 
suppurativa). Br J Dermatol 1999; 141:231-9. 
32. Laffert MV, Helmbold P, Wohlrab J, Fiedler E, Stadie V, Marsch WC. 
Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal 
follicles and at interfollicular epidermis. Exp Dermatol 2009. 
33. Kurokawa I, Nishijima S, Kusumoto K, Senzaki H, Shikata N, Tsubura A. 
Immunohistochemical study of cytokeratins in hidradenitis suppurativa (acne 
inversa). J Int Med Res 2002; 30:131-6. 
34. Gniadecki R, Jemec GB. Lipid raft-enriched stem cell-like keratinocytes in the 
epidermis, hair follicles and sinus tracts in hidradenitis suppurativa. Exp 
Dermatol 2004; 13:361-3. 
35. Hana A, Booken D, Henrich C, Gratchev A, Maas-Szabowski N, Goerdt S, et 
al. Functional significance of non-neuronal acetylcholine in skin epithelia. Life 
Sci 2007; 80:2214-20. 
36. Sellheyer K, Krahl D. "Hidradenitis suppurativa" is acne inversa! An appeal to 
(finally) abandon a misnomer. Int J Dermatol 2005; 44:535-40. 
37. Jemec GB, Gniadecka M. Sebum excretion in hidradenitis suppurativa. 
Dermatology 1997; 194:325-8. 
38. Oprica C, Nord CE. Bacteriology of Hidradenitis Suppurativa. In: Jemec GBE, 
Revuz J, Leyden J, editors. Hidradenitis Suppurativa. Berlin Heidelberg New 
York: Springer; 2006. p. 86-94. 
39. Lapins J, Jarstrand C, Emtestam L. Coagulase-negative staphylococci are the 
most common bacteria found in cultures from the deep portions of hidradenitis 
suppurativa lesions, as obtained by carbon dioxide laser surgery. Br J Dermatol 
1999; 140:90-5. 
40. Brook I, Frazier EH. Aerobic and anaerobic microbiology of axillary 
hidradenitis suppurativa. J Med Microbiol 1999; 48:103-5. 
   42
41. Nordstrom NK, Noble WC. Colonization of the axilla by Propionibacterium 
avidum in relation to age. Appl Environ Microbiol 1984; 47:1360-2. 
42. Hoeffler U. Enzymatic and hemolytic properties of Propionibacterium acnes 
and related bacteria. J Clin Microbiol 1977; 6:555-8. 
43. Jakab E, Zbinden R, Gubler J, Ruef C, von Graevenitz A, Krause M. Severe 
infections caused by Propionibacterium acnes: an underestimated pathogen in 
late postoperative infections. Yale J Biol Med 1996; 69:477-82. 
44. von Eiff C, Peters G, Heilmann C. Pathogenesis of infections due to coagulase-
negative staphylococci. Lancet Infect Dis 2002; 2:677-85. 
45. Yokoi K, Kakikawa M, Kimoto H, Watanabe K, Yasukawa H, Yamakawa A, et 
al. Genetic and biochemical characterization of glutamyl endopeptidase of 
Staphylococcus warneri M. Gene 2001; 281:115-22. 
46. van Kampen MD, Rosenstein R, Gotz F, Egmond MR. Cloning, purification 
and characterisation of Staphylococcus warneri lipase 2. Biochim Biophys Acta 
2001; 1544:229-41. 
47. Slade DE, Powell BW, Mortimer PS. Hidradenitis suppurativa: pathogenesis 
and management. Br J Plast Surg 2003; 56:451-61. 
48. Picardi A, Abeni D. Stressful life events and skin diseases: disentangling 
evidence from myth. Psychother Psychosom 2001; 70:118-36. 
49. Paus R, Theoharides TC, Arck PC. Neuroimmunoendocrine circuitry of the 
'brain-skin connection'. Trends Immunol 2006; 27:32-9. 
50. Zouboulis CC. Acne and sebaceous gland function. Clin Dermatol 2004; 
22:360-6. 
51. Zouboulis CC, Bohm M. Neuroendocrine regulation of sebocytes – a 
pathogenetic link between stress and acne. Exp Dermatol 2004; 13 Suppl 4:31-
5. 
52. Arck P, Paus R. From the brain-skin connection: the neuroendocrine-immune 
misalliance of stress and itch. Neuroimmunomodulation 2006; 13:347-56. 
53. Arck PC, Slominski A, Theoharides TC, Peters EM, Paus R. Neuroimmunology 
of stress: skin takes center stage. J Invest Dermatol 2006; 126:1697-704. 
54. Luger TA. Neuromediators – a crucial component of the skin immune system.  
J Dermatol Sci 2002; 30:87-93. 
55. Luger TA, Lotti T. Neuropeptides: role in inflammatory skin diseases. J Eur 
Acad Dermatol Venereol 1998; 10:207-11. 
56. Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A. Nerve growth 
factor: from neurotrophin to neurokine. Trends Neurosci 1996; 19:514-20. 
57. McEwen BS, Stellar E. Stress and the individual. Mechanisms leading to 
disease. Arch Intern Med 1993; 153:2093-101. 
58. Pincelli C, Fantini F, Giannetti A. Neuropeptides and skin inflammation. 
Dermatology 1993; 187:153-8. 
59. Thompson RJ, Doran JF, Jackson P, Dhillon AP, Rode J. PGP 9.5--a new 
marker for vertebrate neurons and neuroendocrine cells. Brain Res 1983; 
278:224-8. 
60. Day IN, Thompson RJ. UCHL1 (PGP 9.5): Neuronal biomarker and ubiquitin 
system protein. Prog Neurobiol 2009. 
61. Hagforsen E, Nordlind K, Michaelsson G. Skin nerve fibres and their contacts 
with mast cells in patients with palmoplantar pustulosis. Arch Dermatol Res 
2000; 292:269-74. 
62. Al'Abadie MS, Senior HJ, Bleehen SS, Gawkrodger DJ. Neuropeptides and 
general neuronal marker in psoriasis--an immunohistochemical study. Clin Exp 
Dermatol 1995; 20:384-9. 
   
  
43
63. Omdal R, Mellgren SI, Goransson L, Skjesol A, Lindal S, Koldingsnes W, et al. 
Small nerve fiber involvement in systemic lupus erythematosus: a controlled 
study. Arthritis Rheum 2002; 46:1228-32. 
64. Johansson O, Han SW, Enhamre A. Altered cutaneous innervation in psoriatic 
skin as revealed by PGP 9.5 immunohistochemistry. Arch Dermatol Res 1991; 
283:519-23. 
65. Aroni K, Grapsa A, Lazaris AC, Kavantzas N, Kordosis T, Patsouris ES. Tissue 
estimation of protein gene product 9.5 (PGP 9.5) expression and apoptosis in 
vitiligo. Int J Dermatol 2008; 47:911-7. 
66. Sugiura H, Omoto M, Hirota Y, Danno K, Uehara M. Density and fine structure 
of peripheral nerves in various skin lesions of atopic dermatitis. Arch Dermatol 
Res 1997; 289:125-31. 
67. Tobin D, Nabarro G, Baart de la Faille H, van Vloten WA, van der Putte SC, 
Schuurman HJ. Increased number of immunoreactive nerve fibers in atopic 
dermatitis. J Allergy Clin Immunol 1992; 90:613-22. 
68. El-Nour H, Lundeberg L, Al-Tawil R, Granlund A, Lonne-Rahm SB, Nordlind 
K. Upregulation of the axonal growth and the expression of substance P and its 
NK1 receptor in human allergic contact dermatitis. Immunopharmacol 
Immunotoxicol 2006; 28:621-31. 
69. El-Nour H, Santos A, Nordin M, Jonsson P, Svensson M, Nordlind K, et al. 
Neuronal changes in psoriasis exacerbation. J Eur Acad Dermatol Venereol 
2009. 
70. Jemec GB. Medical treatment of hidradenitis suppurativa. Expert Opin 
Pharmacother 2004; 5:1767-70. 
71. Sartorius K, Boer J, Jemec GBE. Topical Treatment. In: Jemec GBE, Revuz J, 
Leyden J, editors. Hidradenitis Suppurativa. Berlin Heidelberg New York: 
Springer; 2006. p. 150-60. 
72. Clemmensen OJ. Topical treatment of hidradenitis suppurativa with 
clindamycin. Int J Dermatol 1983; 22:325-8. 
73. Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in 
the treatment of hidradenitis suppurativa. J Am Acad Dermatol 1998; 39:971-4. 
74. Gener G, Canoui-Poitrine F, Revuz JE, Faye O, Poli F, Gabison G, et al. 
Combination therapy with clindamycin and rifampicin for hidradenitis 
suppurativa: a series of 116 consecutive patients. Dermatology 2009; 219:148-
54. 
75. Mendonca CO, Griffiths CE. Clindamycin and rifampicin combination therapy 
for hidradenitis suppurativa. Br J Dermatol 2006; 154:977-8. 
76. van der Zee HH, Boer J, Prens EP, Jemec GB. The effect of combined 
treatment with oral clindamycin and oral rifampicin in patients with hidradenitis 
suppurativa. Dermatology 2009; 219:143-7. 
77. Boer J, van Gemert MJ. Long-term results of isotretinoin in the treatment of 68 
patients with hidradenitis suppurativa. J Am Acad Dermatol 1999; 40:73-6. 
78. Sawers RS, Randall VA, Ebling FJ. Control of hidradenitis suppurativa in 
women using combined antiandrogen (cyproterone acetate) and oestrogen 
therapy. Br J Dermatol 1986; 115:269-74. 
79. Mortimer PS, Dawber RP, Gales MA, Moore RA. A double-blind controlled 
cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. 
Br J Dermatol 1986; 115:263-8. 
80. Kraft JN, Searles GE. Hidradenitis suppurativa in 64 female patients: 
retrospective study comparing oral antibiotics and antiandrogen therapy. J 
Cutan Med Surg 2007; 11:125-31. 
   44
81. Farrell AM, Randall VA, Vafaee T, Dawber RP. Finasteride as a therapy for 
hidradenitis suppurativa. Br J Dermatol 1999; 141:1138-9. 
82. Joseph MA, Jayaseelan E, Ganapathi B, Stephen J. Hidradenitis suppurativa 
treated with finasteride. J Dermatolog Treat 2005; 16:75-8. 
83. Jemec GB. Methotrexate is of limited value in the treatment of hidradenitis 
suppurativa. Clin Exp Dermatol 2002; 27:528-9. 
84. Rose RF, Goodfield MJ, Clark SM. Treatment of recalcitrant hidradenitis 
suppurativa with oral ciclosporin. Clin Exp Dermatol 2006; 31:154-5. 
85. Buckley DA, Rogers S. Cyclosporin-responsive hidradenitis suppurativa. J R 
Soc Med 1995; 88:289P-90P. 
86. Gupta AK, Ellis CN, Nickoloff BJ, Goldfarb MT, Ho VC, Rocher LL, et al. 
Oral cyclosporine in the treatment of inflammatory and noninflammatory 
dermatoses. A clinical and immunopathologic analysis. Arch Dermatol 1990; 
126:339-50. 
87. Kaur MR, Lewis HM. Hidradenitis suppurativa treated with dapsone: A case 
series of five patients. J Dermatolog Treat 2006; 17:211-3. 
88. Haslund P, Lee RA, Jemec GB. Treatment of Hidradenitis Suppurativa with 
Tumour Necrosis Factor-alpha Inhibitors. Acta Derm Venereol 2009; 89:595-
600. 
89. Lebwohl B, Sapadin AN. Infliximab for the treatment of hidradenitis 
suppurativa. J Am Acad Dermatol 2003; 49:S275-6. 
90. Martinez F, Nos P, Benlloch S, Ponce J. Hidradenitis suppurativa and Crohn's 
disease: response to treatment with infliximab. Inflamm Bowel Dis 2001; 7:323-
6. 
91. Ritz JP, Runkel N, Haier J, Buhr HJ. Extent of surgery and recurrence rate of 
hidradenitis suppurativa. Int J Colorectal Dis 1998; 13:164-8. 
92. Kagan RJ, Yakuboff KP, Warner P, Warden GD. Surgical treatment of 
hidradenitis suppurativa: a 10-year experience. Surgery 2005; 138:734-40; 
discussion 40-1. 
93. Morgan WP, Harding KG, Hughes LE. A comparison of skin grafting and 
healing by granulation, following axillary excision for hidradenitis suppurativa. 
Ann R Coll Surg Engl 1983; 65:235-6. 
94. Morgan WP, Harding KG, Richardson G, Hughes LE. The use of silastic foam 
dressing in the treatment of advanced hidradenitis suppurativa. Br J Surg 1980; 
67:277-80. 
95. Ramasastry SS, Conklin WT, Granick MS, Futrell JW. Surgical management of 
massive perianal hidradenitis suppurativa. Ann Plast Surg 1985; 15:218-23. 
96. Silverberg B, Smoot CE, Landa SJ, Parsons RW. Hidradenitis suppurativa: 
patient satisfaction with wound healing by secondary intention. Plast Reconstr 
Surg 1987; 79:555-9. 
97. Dalrymple JC, Monaghan JM. Treatment of hidradenitis suppurativa with the 
carbon dioxide laser. Br J Surg 1987; 74:420. 
98. Finley EM, Ratz JL. Treatment of hidradenitis suppurativa with carbon dioxide 
laser excision and second-intention healing. J Am Acad Dermatol 1996; 34:465-
9. 
99. Lapins J, Marcusson JA, Emtestam L. Surgical treatment of chronic hidradenitis 
suppurativa: CO2 laser stripping-secondary intention technique. Br J Dermatol 
1994; 131:551-6. 
100. Sherman AI, Reid R. CO2 laser for suppurative hidradenitis of the vulva. J 
Reprod Med 1991; 36:113-7. 
   
  
45
101. Fitzpatrick RE, Goldman MP. Advances in carbon dioxide laser surgery. Clin 
Dermatol 1995; 13:35-47. 
102. Madan V, Hindle E, Hussain W, August PJ. Outcomes of treatment of nine 
cases of recalcitrant severe hidradenitis suppurativa with carbon dioxide laser. 
Br J Dermatol 2008; 159:1309-14. 
103. Hazen PG, Hazen BP. Hidradenitis Suppurativa: Successful Treatment Using 
Carbon Dioxide Laser Excision and Marsupialization. Dermatol Surg 2009. 
104. Lee RA, Yoon A, Kist J. Hidradenitis suppurativa: an update. Adv Dermatol 
2007; 23:289-306. 
105. Tsianos EV, Dalekos GN, Tzermias C, Merkouropoulos M, Hatzis J. 
Hidradenitis suppurativa in Crohn's disease. A further support to this 
association. J Clin Gastroenterol 1995; 20:151-3. 
106. van der Zee HH, van der Woude CJ, Florencia EF, Prens EP. Hidradenitis 
suppurativa and inflammatory bowel disease: are they associated? Results of a 
pilot study. Br J Dermatol 2009. 
107. Lapins J, Ye W, Nyren O, Emtestam L. Incidence of cancer among patients 
with hidradenitis suppurativa. Arch Dermatol 2001; 137:730-4. 
108. Constantinou C, Widom K, Desantis J, Obmann M. Hidradenitis suppurativa 
complicated by squamous cell carcinoma. Am Surg 2008; 74:1177-81. 
109. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the 
science of quality of life into practice: What do dermatology life quality index 
scores mean? J Invest Dermatol 2005; 125:659-64. 
110. Heimdahl A, Hall G, Hedberg M, Sandberg H, Söder PO, Tuner K, et al. 
Detection and quantitation by lysis-filtration of bacteremia after different oral 
surgical procedures. J Clin Microbiol 1990; 28:2205-9. 
111. Heimdahl A, Josefsson K, von Konow L, Nord CE. Detection of anaerobic 
bacteria in blood cultures by lysis filtration. Eur J Clin Microbiol 1985; 4:404-
7. 
112. Sullivan NM, Sutter VL, Finegold SM. Practical aerobic membrane filtration 
blood culture technique: clinical blood culture trial. J Clin Microbiol 1975; 
1:37-43. 
113. Ljungberg A, Johansson O. Methodological aspects on immunohistochemistry 
in dermatology with special reference to neuronal markers. Histochem J 1993; 
25:735-45. 
114. Colton T. Statistics in Medicine. Boston: Little, Brown and Company, 1974. 
115. Jemec GB, Wulf HC. Patient-physician consensus on quality of life in 
dermatology. Clin Exp Dermatol 1996; 21:177-9. 
116. Holm EA, Wulf HC, Stegmann H, Jemec GB. Life quality assessment among 
patients with atopic eczema. Br J Dermatol 2006; 154:719-25. 
117. Fardet L, Dupuy A, Kerob D, Levy A, Allez M, Begon E, et al. Infliximab for 
severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive 
patients. J Am Acad Dermatol 2007; 56:624-8. 
118. Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in 
hidradenitis suppurativa. Br J Dermatol 2008; 158:370-4. 
119. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, Petropoulou H, 
Baziaka F, Karagianni V, et al. An open-label phase II study of the safety and 
efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol 
2008; 158:567-72. 
120. Brunasso AM, Delfino C, Massone C. Hidradenitis suppurativa: are tumour 
necrosis factor-alpha blockers the ultimate alternative? Br J Dermatol 2008; 
159:761-3. 
   46
121. Reid R. Physical and surgical principles governing carbon dioxide laser surgery 
on the skin. Dermatol Clin 1991; 9:297-316. 
122. Banerjee AK. Surgical treatment of hidradenitis suppurativa. Br J Surg 1992; 
79:863-6. 
123. Harrison BJ, Mudge M, Hughes LE. Recurrence after surgical treatment of 
hidradenitis suppurativa. Br Med J (Clin Res Ed) 1987; 294:487-9. 
124. Gill VJ, Zierdt CH, Wu TC, Stock F, Pizzo PA, MacLowry JD. Comparison of 
lysis-centrifugation with lysis-filtration and a conventional unvented bottle for 
blood cultures. J Clin Microbiol 1984; 20:927-32. 
125. Halpern AC, Leyden JJ, Dzubow LM, McGinley KJ. The incidence of 
bacteremia in skin surgery of the head and neck. J Am Acad Dermatol 1988; 
19:112-6. 
126. Mullarky MB, Norris CW, Goldberg ID. The efficacy of the CO2 laser in the 
sterilization of skin seeded with bacteria: survival at the skin surface and in the 
plume emissions. Laryngoscope 1985; 95:186-7. 
127. al-Qattan MM, Stranc MF, Jarmuske M, Hoban DJ. Wound sterilization: CO2 
laser versus iodine. Br J Plast Surg 1989; 42:380-4. 
128. Stranc MF, Yang FW. Wound sterilisation: cautery vs CO2 laser. Br J Plast 
Surg 1992; 45:536-9. 
129. Kamath U, Singer C, Isenberg HD. Clinical significance of Staphylococcus 
warneri bacteremia. J Clin Microbiol 1992; 30:261-4. 
130. Buttery JP, Easton M, Pearson SR, Hogg GG. Pediatric bacteremia due to 
Staphylococcus warneri: microbiological, epidemiological, and clinical 
features. J Clin Microbiol 1997; 35:2174-7. 
131. Camisa C, Sexton C, Friedman C. Treatment of hidradenitis suppurativa with 
combination hypothalamic-pituitary-ovarian and adrenal suppression. A case 
report. J Reprod Med 1989; 34:543-6. 
132. Bogers JW, Minderhoud-Bassie W, Huikeshoven FJ. A case of hidradenitis 
suppurativa treated with gonadotropin-releasing hormone agonist and by total 
abdominal hysterectomy with bilateral salpingo-oophorectomy. Am J Obstet 
Gynecol 1992; 167:517-8. 
133. Johansson O, Wang L, Hilliges M, Liang Y. Intraepidermal nerves in human 
skin: PGP 9.5 immunohistochemistry with special reference to the nerve density 
in skin from different body regions. J Peripher Nerv Syst 1999; 4:43-52. 
134. Olerud JE, Chiu DS, Usui ML, Gibran NS, Ansel JC. Protein gene product 9.5 
is expressed by fibroblasts in human cutaneous wounds. J Invest Dermatol 
1998; 111:565-72. 
135. Jemec GB, Faber M, Gutschik E, Wendelboe P. The bacteriology of 
hidradenitis suppurativa. Dermatology 1996; 193:203-6. 
136. Slominski A. Neuroendocrine system of the skin. Dermatology 2005; 211:199-
208. 
137. Mastoraki A, Ioannidis E, Patsouris E, Safioleas M, Aroni K. PGP 9.5 
expression in cutaneous keratoacanthomas and squamous cell carcinomas. Arch 
Dermatol Res 2009; 301:653-8. 
138. Thomsen NO, Englund E, Thrainsdottir S, Rosen I, Dahlin LB. Intraepidermal 
nerve fibre density at wrist level in diabetic and non-diabetic patients. Diabet 
Med 2009; 26:1120-6. 
139. Kleyn CE, Schneider L, Saraceno R, Mantovani C, Richards HL, Fortune DG, 
et al. The effects of acute social stress on epidermal Langerhans' cell frequency 
and expression of cutaneous neuropeptides. J Invest Dermatol 2008; 128:1273-
9. 
   
  
47
140. Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis 
suppurativa. Br J Dermatol 2006; 154:726-9. 
141. Gupta AK, Skinner AR. A review of the use of infliximab to manage cutaneous 
dermatoses. J Cutan Med Surg 2004; 8:77-89. 
142. Roussomoustakaki M, Dimoulios P, Chatzicostas C, Kritikos HD, Romanos J, 
Panayiotides JG, et al. Hidradenitis suppurativa associated with Crohn's disease 
and spondyloarthropathy: response to anti-TNF therapy. J Gastroenterol 2003; 
38:1000-4. 
143. Sullivan TP, Welsh E, Kerdel FA, Burdick AE, Kirsner RS. Infliximab for 
hidradenitis suppurativa. Br J Dermatol 2003; 149:1046-9. 
144. Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab 
therapy for patients with moderate to severe hidradenitis suppurativa: A 
randomized, double-blind, placebo-controlled crossover trial. J Am Acad 
Dermatol; 62:205-17. 
145. Tierney E, Mahmoud BH, Hexsel C, Ozog D, Hamzavi I. Randomized control 
trial for the treatment of hidradenitis suppurativa with a neodymium-doped 
yttrium aluminium garnet laser. Dermatol Surg 2009; 35:1188-98. 
146. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the 
ecological balance of human microflora. Lancet Infect Dis 2001; 1:101-14. 
147. Dreno B. Topical antibacterial therapy for acne vulgaris. Drugs 2004; 64:2389-
97. 
148. Thiboutot D, Gollnick H, Bettoli V, Dreno B, Kang S, Leyden JJ, et al. New 
insights into the management of acne: an update from the Global Alliance to 
Improve Outcomes in Acne group. J Am Acad Dermatol 2009; 60:S1-50. 
149. Mallbris L, Ritchlin CT, Ståhle M. Metabolic disorders in patients with 
psoriasis and psoriatic arthritis. Curr Rheumatol Rep 2006; 8:355-63. 
150. Hagforsen E, Edvinsson M, Nordlind K, Michaelsson G. Expression of 
nicotinic receptors in the skin of patients with palmoplantar pustulosis. Br J 
Dermatol 2002; 146:383-91. 
151. Simonart T. Hidradenitis suppurativa and smoking. J Am Acad Dermatol; 
62:149-50. 
152. Revuz J. [Modifications to the Sartorius score and instructions for evaluating 
the severity of suppurative hidradenitis]. Ann Dermatol Venereol 2007; 
134:173-4. 
153. Pelekanou A, Kanni T, Savva A, Mouktaroudi M, Raftogiannis M, Kotsaki A, 
et al. Long-term efficacy of etanercept in hidradenitis suppurativa: results from 
an open-label phase II prospective trial. Exp Dermatol 2009. 
154. Sotiriou E, Apalla Z, Ioannidos D. Etanercept for the treatment of hidradenitis 
suppurativa. Acta Derm Venereol 2009; 89:82-3. 
155. Sotiriou E, Apalla Z, Vakirlis E, Ioannides D. Efficacy of adalimumab in 
recalcitrant hidradenitis suppurativa. Eur J Dermatol 2009; 19:180-1. 
156. Sotiriou E, Apalla Z, Maliamani F, Ioannides D. Treatment of recalcitrant 
hidradenitis suppurativa with photodynamic therapy: report of five cases. Clin 
Exp Dermatol 2009; 34: 235-6. 
 
 
